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ABSTRACT OF THE DISSERTATION
Functional Consequences of Cantu Syndrome Associated Mutations in the ATP Sensitive
Potassium Channel
by
Paige E. Cooper
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2015
Professor Colin G. Nichols, Chair
ATP-sensitive potassium (KATP) channels are composed of inward-rectifying potassium channel
pore-forming subunits (Kir6.1 and Kir6.2, encoded by KCNJ8 and KCNJ11, respectively) and
regulatory sulfonylurea receptor subunits (SUR1 and SUR2, encoded by ABCC8 and ABCC9,
respectively). These channels couple metabolism to excitability in multiple tissues. Mutations in
ABCC9 have been linked to Cantú syndrome (CS), a multi-organ disease characterized by
congenital hypertrichosis, distinct facial features, osteochondrodysplasia, and cardiac defects.
Additionally, two ABCC9 mutation-negative patients, exhibiting clinical hallmarks of CS, have
been identified as having KCNJ8 mutations. This body of work is focused on determining the
functional consequences and molecular mechanisms of documented CS-associated ABCC9 and
identified KCNJ8 mutations. These mutations were engineered into recombinant cDNA clones
and expressed as functional channels. Macroscopic rubidium (86Rb+) efflux assay experiments
demonstrate that KATP channels formed with SUR2 and Kir6.1 mutant subunits both result in
gain of function in KATP activity. Inside-out patch-clamp electrophysiological experiments show
that there are at least 3 mechanisms by which these mutations alter KATP channel activity,

vii

including: 1) an SUR2 mutation that indirectly decreases ATP sensitivity by allosteric changes,
2) a Kir6.1 mutation that increases channel-open probability, and thereby indirectly decreases
ATP sensitivity, and 3) mutations in SUR2 that increase channel activation in response to
MgADP. Taken together, CS-associated ABCC9 or KCNJ8 mutations result in enhanced KATP
activity that underlies the cardinal features of Cantu Syndrome.

viii

CHAPTER L: INTRODUCTION
Inwardly-rectifying potassium (Kir) channels are a class of channels generated by 7 gene subfamilies. All Kir channels are made of tetramers of Kir subunits and all require
phosphatidylinositol 4,5-bisphosphate (PIP2) for channel activity (Huang et al., 1998; Zhang et
al., 1999). These channels are expressed widely throughout the human body and play important
roles in regulating membrane potential. Disruption in Kir channel activity is linked to a variety of
diseases (Pattnaik et al., 2012). The Kir6.X sub-family members generate the pores of adenosine
triphosphate (ATP) sensitive potassium channels, which is the focus of this project.
The ATP-sensitive potassium current (IK,ATP) was first described, in cardiomyocytes, as
an outward current that is activated during metabolic poisoning and inhibited by ATP (Noma,
1983). Over the next several years, additional tissues were found to have IK,ATP (Cook and Hales,
1984; Spruce et al., 1985). Capitalizing on the sensitivity of the current to sulfonylurea drugs,
Aguilar-Bryan et al. identified and then purified the heteromeric complex of pore and auxillary
subunits that comprise the ATP-sensitive potassium (KATP) channel (Aguilar-Bryan and Bryan,
1999). The genes that encode the pore and auxiliary subunits are found in pairs on two different
human chromosomes. On human chromosome 11p at position 15.1, KCNJ11, which encodes the
pore-forming Kir6.2 subunit, is directly downstream of ABCC8, which encodes the auxiliary
subunit SUR1 (Aguilar-Bryan et al., 1995). Conversely, on human chromosome 12p at position
11.23, KCNJ8, which encodes the pore-forming subunit Kir6.1, is located downstream of
ABCC9, which encodes the auxiliary subunit SUR2 (Figure 1.1) (Chutkow et al., 1996; Inagaki
et al., 1995b).
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Figure 1.1- The genes encoding KATP channel proteins. Cartoon
representation of human chromosomes 11 and 12, where the genes
encoding KATP channels are found. Each box represents the gene denoted in
italics and the name of the encoded protein is indicated above.
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1.1 KATP Channel Protein Topology
The pore-forming subunit proteins Kir6.2 and Kir6.1, which are encoded by KCNJ11 and
KCNJ8, respectively, are members of the inward- rectifying potassium (Kir) channel family.
Crystallization of the bacterial KcsA potassium channel provided a structural model for the Kir6
family (Figure 1.2A). The N and C termini orient within the cytoplasm with two transmembrane
helices connected by a short loop (P-loop), which forms the pore and ion selectivity filter (Doyle
et al., 1998). The two Kir6.X family member proteins share ~70% sequence identity (Inagaki et
al., 1995a).
KATP channels formed with either Kir6.2 or Kir6.1 exhibit distinct gating and
conductance. Kir6.2 channels spontaneously activate in the absence of ATP; however, Kir6.1
channels require the application of activating nucleotides (Kondo et al., 1998). Second, the
single-channel conductance for Kir6.2, is double that of Kir6.1 conductance (Inagaki et al.,
1995a; Isomoto et al., 1996; Sakura et al., 1995; Yamada et al., 1997). In chimera studies,
replacing the Kir6.2 extracellular linker and the p-loop with that of Kir6.1 had no effect on
gating but lowered the unitary conductance, implying that this region determines the unitary
conductance (Kondo et al., 1998; Kono et al., 2000; Repunte et al., 1999). Conversely, additional
chimera studies demonstrate that the unique N-terminus and C-terminus of Kir6.2 are necessary
for spontaneous channel activity.
The sulfonylurea receptor (SUR) 1 and 2, the KATP auxiliary subunit protein isoforms
encoded by ABCC8 and ABCC9, respectively, are members of the ATP-binding Cassette (ABC)
family (Figure 1.1). SUR1 and SUR2 share ~68% sequence identity homology (Inagaki et al.,
1996) and are oriented in the membrane with an extracellular N terminus and a cytoplasmic C
terminus (Figure 1.2A). As first predicted by hydrophobicity mapping and later confirmed using
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Figure 1.2- Topology and stoichiometry of the KATP channel complex. A cartoon
of a KATP channel Kir6.X (blue) and a SURX (yellow) subunit orientation within the
membrane. The P-loop and the nucleotide binding domains (NBDs) are boxed in red
and green, respectively (A). The 4:4 stoichiometry of Kir6.X to SURX proteins
which form the KATP channel complex is depicted in (B).
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biotinylation assays and immunofluorescence, the SUR protein contains 17 transmembrane
helices grouped into 3 domains (TMD0-2) connected and followed by cytoplasmic loops that
form two nucleotide-binding domains (NBD) (Figure 1.2A) (Conti et al., 2001; Tusnady et al.,
1997). SUR2 has two major splice variants, SUR2A and SUR2B (Inagaki et al., 1996; Isomoto et
al., 1996). Both SUR1 and SUR2 have additional splice sites, but the resulting variants are
poorly understood (Shi et al., 2005).
1.2 KATP Channel Stoichiometry/Trafficking/Subunit Pairing
The size of the purified KATP channel complex suggested that each KATP channel is formed by
four Kir6.X and four SURX subunits. 1:1 Kir6.2-SUR1 fusion proteins forming functional
channels provided supporting evidence (Clement et al., 1997) for this hypothesis. The currentvoltage profiles of channels formed with various heteromeric molar ratios of wild-type Kir6.2
were compared with a strongly rectifying Kir6.2 mutant. This work provided direct evidence
that four Kir6.X subunits form the pore (Shyng and Nichols, 1997). The electrophysiological
properties of KATP channels produced from an engineered fusion construct made of one Kir6.2
and one SUR1 were identical to those produced by co-expression of Kir6.x and SURX subunits,
thus confirming a 4:4 stoichiometry of Kir6.x and SURX subunits forming KATP channels
(Figure 1.2B) (Shyng and Nichols, 1997).
The short Arg-Lys-Arg endoplasmic reticulum (ER) retention signals in Kir6.X at the Cterminus and in SURX between TMD1 and NBF1 are mutually masked in the full complex,,
allowing for translocation of these subunits to the plasma membrane (Zerangue et al., 1999).
The retention signal on each Kir6.X and SURX subunit also obligates correct subunit pairing and
stoichiometry before trafficking to the plasma membrane (Zerangue et al., 1999). However,
removing the last 30 amino acids from the C-terminus of Kir6.2, which includes the ER-retention
5

signal, allows Kir6.2 to traffic and function alone on the plasma membrane (Tucker et al., 1997).
As both pore and auxiliary subunits come in multiple isoforms, the resulting KATP channels can
be formed with multiple subunit combinations. Studies in heterologous expression systems have
shown that all combinations are able to traffic and function at the cell membrane (Shi et al.,
2005). Table 1.1 lists subunit combinations that have been identified in native tissues.
1.3 KATP Channel Activity Regulation
KATP channels couple cell metabolism and excitability in multiple cell types. Importantly, there
are a variety of physiological and pharmacological modulators of KATP channels, some of which
are discussed in detail below.
1.3.1 Physiological Modulators
1.3.1.i Nucleotides
In addition to forming the pore of the channel, the Kir6.X subunits bind inhibitory ATP and
adenosine diphosphate (ADP) (Mg-free) (Figure 1.3A) (Tucker et al., 1997). Truncation and
mutagenesis experiments demonstrate that both the N- and C-termini of Kir6.X contribute to the
ATP-sensitivity (Drain et al., 1998; Koster et al., 1999; Tucker et al., 1998).
Adenylylimidodiphosphate (AMP-PNP), a non-metabolizable form of ATP, produces an
inhibitory response identical to that of ATP, indicating that binding, not hydrolysis, of ATP is
sufficient for KATP inhibition (Inagaki et al., 1995a). The specificity of ATP binding and
inhibition was validated in photoaffinity labeling experiments. Additionally, numerous
triphosphates, including: guanine, inosine, cytidine or uridine, fail to inhibit IK,ATP currents in
both recombinant systems and in native tissues, further supporting the specificity of the KATP

6

Table 1.1- Native KATP Channel Composition in Various Tissues
TISSUE
BRAIN
Hippocampus

Channel
KATP
COMPOSITION
Kir6.2/SUR1
Kir6.2/SUR2
Kir6.1/SUR1
Kir6.1/SUR2

REFERENCES
Zawar et al. J Physiol 514: 327-341, 1999
Hyllienmark, L. and Brismar, T. Journal of Physiol, 496,
155± 164, 1996
Fujimura, N. et al. Journal of Neurophysiology, 77, 378±
385, 1997
Spanswick, D et al. Nature, 390, 521-525, 1997
Liss, B. et al. Journal of Physiology 527, 114P-115P, 2000
Lee, K. et al. Journal of Physiology 515, 439-452, 1999
Miki T et al. Nat Neurosci. May;4(5):507-12, 2001
Ashford, M. L et al. Pflugers Archives, 415, 479± 483,
1990
Karschin, A. et al. Journal of Physiology 509, 339± 346,
1998
Trapp, S. and Ballanyi, K., Journal of Physiology, 487,
37± 50, 1995
Lee, K. et al. Journal of Physiology, 510, 441± 453, 1998
Stanford, I. M. and Lacey, M. G. Neuroscience, 74, 499±
509, 1996
Liss, B. et al. Embo Journal, 18,833± 846, 1999
Schwanstecher, C. and Panten, U. Naunyn Schmiedebergs
Archives of Pharmacology, 348, 113± 117, 1993
Roeper, J et al. Journal of Physiology, 430, P130. 1990.
Babenko AP et al. Circ Res 83: 1132–1143, 1998

Hypothalamus

Kir6.1/SUR1
Kir6.2/SUR1

Brain Stem

Kir6.2/SUR1

Basal Ganglia
-Striatum
-Substantia nigra

Kir6.1/SUR1
Kir6.2/SUR2B
Kir6.2/SUR1

HEART
Ventricle
Atrium

Kir6.2/SUR2A
Kir6.2/SUR1

Flagg TP et al.Circ Res 103: 1458–1465, 2008
Glukhov AV et al. J Mol Cell Cardiol 48: 152–160, 2010

Conduction
System

Kir6.1/SUR2A
Kir6.2/SUR2A

PANCREATIC
BETA CELL

Kir6.2/SUR1

Han X et al.J Physiol 490: 337–350, 1996
Fukuzaki K et al. J Physiol 586: 2767–2778, 2008
Kakei M and Noma A. J Physiol 352: 265–284, 1984
Light PE et al. Cardiovasc Res 44: 356–369, 1999
Inagaki N et al. Science Nov17;270(5239):1166-70, 1995

SKELETAL
MUSCLE

Kir6.2/SUR2A
Kir6.2/SUR1

Tricarico D et al. Proc Natl Acad Sci USA 103: 1118–
1123, 2006

VASCULAR
SMOOTH
MUSCLE

Kir6.1/SUR2B
Kir6.2/SUR2B

Isomoto S et al. J Biol Chem 271: 24321–24324, 1996
Zhang HL and Bolton TB. Br J Pharmacol 118: 105–114.
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Figure 1.3- Nucleotide Binding and Regulation of the KATP channel.
The Kir6.X is represented in blue and the SURX subunit is represented
in yellow. ATP and ADP (No Mg2+), which both bind to the Kir6.X
subunits to inhibit the channel, are represented by red and green circles,
respectively. MgADP binds to the Nucleotide Binding Domains (NBDs)
within the SURX subunit (A). The NBD region is enlarged in the square
region and the Walker A and Walker B motifs, which are within the
NBDs, are represented by purple and gray regions, respectively. In these
Walker motifs ATP and MgADP have been shown to bind. Mg2+ is
represented by light blue hexagons attached to ADP (B).
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channel to regulation by ATP (Koster et al., 1999; Lederer and Nichols, 1989; Tanabe et al.,
2000; Tucker et al., 1998).
Channels composed of Kir6.2 alone, which traffic after truncation of the ER retention
signal, have decreased sensitivity to ATP inhibition compared to WT channels composed of
Kir6.2 and SUR1 (Tucker et al., 1997). This finding suggests that SUR subunits also play a role
in regulating channel activity. Photoaffinity labeling using 8-azido-[α-32P]ATP or 8-azido-[γ32

P]ATP in cells overexpressing SUR1 demonstrated that ATP binds the SUR subunit directly

(Ueda et al., 1997). MgADP works at the level of the NBDs in SUR to activate the channel
(Nichols et al., 1996). Nucleotide binding folds (NBFs), which are conserved in all ABC proteins
including SURX subunits, contain Walker A and Walker B nucleotide-binding motifs (Figure
1.3B) (Higgins, 1992). Nucleotide binding sites in SURX were identified by mutagenesis of the
conserved Walker A and Walker B regions in both NBF1 and NBF2. Free ATP binds to NBF1
and MgADP interacts with NBF2, but can also alter ATP binding to NBF1 (Ueda et al., 1997).
Disruption of the NBF2 Walker B motif or linker region within SUR1 completely
abolishes the activating effect of MgADP, without altering ATP-sensitivity. Conversely,
mutations at the equivalent positions in the NBF1 Walker B motif only alter activation kinetics
(Shyng et al., 1997). Expression of SUR1 mutagenized at lysine residue(s) within Walker A
motifs in NBF1, NBF2 or both, with Kir6.2-WT, produced KATP channels with increased ATPsensitivity (no Mg2+) and with MgADP inhibition instead of activation (Gribble et al., 1997).
Taken together, the Walker A motif in NBF1 and both Walker A and Walker B motifs in NBF2
are required for MgADP activation of KATP channels (Figure 1.3B). MgADP stimulation differs
among the SUR isoforms, where SUR1-based channels are more stimulated than SUR2A (Masia
et al., 2005). The differences in nucleotide-binding affinities among the SUR isoforms may
9

account for some of the diversity of behavior among the different channel compositions (Matsuo
et al., 2000).
1.3.1.ii Phosphorylation
PKC
Direct modulation via either the protein kinase C (PKC) pathway or KATP channel activity
modulates vascular tone. In addition, activation of PKC can decrease KATP channel activity
indirectly to influence tone. The response of KATP channels to PKC activation could occur
because: 1) KATP channels are directly regulated by PKC signaling or 2) PKC activation inhibits
KATP channel indirectly by depleting PIP2 from the membrane. Stable Kir6.1+SUR2B and
Kir6.2+SUR2B cell lines were used to monitor KATP channel activity response to
pharmacological activation of PKC in combination with inhibitors of the PKC signaling cascade,
providing some of the first evidence that Kir6.1 based channels are directly regulated by PKC
(Quinn et al., 2003).
Additional engineered chimera studies demonstrated that N- and C-termini of Kir6.1 are
necessary for PKC regulation. Use of electrophysiology and phosphorylation assays revealed that
individual intracellular serine residues, which are unique to the C-terminus of Kir6.1, mutated to
alanine do not prevent PKC inhibition. However, mutating these serine residues simultaneously
abolishes PKC inhibition of KATP channels. Taken together, several serine residues in the Cterminus of Kir6.1 are required for direct PKC phosphorylation and inhibition of KATP channel
activity (Figure 1.4A) (Shi et al., 2008).
The ability of PKC to inhibit Kir6.1-based KATP channels might suggest that KATP
channel activation results from dephosphorylation by phosphatases. Electrophysiological data
10

from isolated rat aortic smooth muscle show that different structural classes of Ca2+-dependent
protein phosphatase type 2B (PP2B) inhibitors can inhibit IK,ATP. These results suggest that in
native tissue, PP2B phosphatase activity can regulate KATP channel activity (Figure 1.4A)
(Wilson et al., 2000).
PKA
At least two studies have shown that KATP channels composed of Kir6.1+SUR2B are activated
by PKA in a cAMP-dependent manner (Quinn et al., 2004; Shi et al., 2007). There is conflicting
evidence however about the actual residues phosphorylated by PKA. Quinn et al. concluded that
a serine residue in Kir6.1 and/or a serine and a threonine residue in SUR2B are phosphorylation
sites for PKA(Quinn et al., 2004). On the other hand, Shi et al. made alanine substitutions at
these residues and found no differences in PKA sensitivity of KATP channel currents, leading
them to conclude that these sites are not relevant. They went on to identify a single serine residue
in SUR2B as the only PKA phosphorylation site, which they confirmed by in vitro
phosphorylation assays (Figure 1.4B) (Shi et al., 2007).
Despite the debate over which specific Kir6.1 and/or SUR2B residue(s) PKA
phosphorylates (Quinn et al., 2004; Shi et al., 2007), it is agreed that PKA phosphorylates KATP
channels directly to regulate vascular tone. There has therefore been an interest in identifying
potential phosphatase(s) to counter activation of KATP channel after PKA phosphorylation (Orie
et al., 2009). Dephosphorylation of KATP would inhibit KATP channel activity and, noting that
Kir6.1+2B activity decreases in high intracellular Ca2+, the Ca2+-dependent phosphatase
calcineurin was tested as a potential KATP channel phosphatase. Multiple chemically unrelated
calcineurin inhibitors increase both in vitro phosphorylation of KATP channel subunits and KATP

11

A

B

Figure 1.4- PKA and PKC signaling pathway regulation of the
KATP channel. Cartoon of KATP channel regulation by PKC (A) and
PKA (B) pathways in which Kir6.1 is depicted in blue surrounded by
SUR2B in yellow. Red dots depict phosphorylation sites on Kir6.1 cterminus or SUR2B as described in the text.
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channel activity (Figure 1.4B) (Orie et al., 2009). In the presence of a PKA catalytic domain that
is constitutively active, calcineurin has no effect on KATP channel activity. This observation
indicates that calcineurin directly dephosphorylates KATP channels to regulate channel activity
(Orie et al., 2009).
1.3.1.iii pH
Increases in intracellular pH result in increases in KATP channel current, in the presence or
absence of ATP, in isolated rat beta cells (Misler et al., 1989). Further evidence for KATP channel
pH sensitivity has been obtained from studies on inside-out patches from Xenopus oocytes
expressing Kir6.2+SUR1 and from isolated mouse cardiomyocytes (Baukrowitz et al., 1999).
Histidine is the most common amino acid protonated or deprotonated at physiological pH. By
mutating each of the 9 intracellular histidine residues in Kir6.2 to amino acids with nontitratable side chains, a single residue was identified as the pH-sensing residue in KATP channels
(Baukrowitz et al., 1999).
1.3.2 Pharmacological Modulation
In addition to physiological regulation, KATP channel activity is modulated by distinct
pharmacological agents. The molecular basis and action of these modulators are discussed
below.
1.3.2.i K channel openers (KCOs)
Diverse classes of drugs called K+ channel openers (KCOs) activate KATP channels by binding to
the SUR subunits (Inagaki et al., 1996). The ability of individual KCOs to activate channels is
dependent on the SUR isoform. Whereas SUR1-containing channels are activated specifically by
diazoxide (Inagaki et al., 1995a), SUR2A -containing channels are effectively activated by all
13

KCOs except diazoxide (Inagaki et al., 1996). SUR2B-containing channels respond to all KCOs
(Isomoto et al., 1996).
Synthesis and study of SUR chimera proteins has demonstrated that KCOs such as
levcromakalim, cromakalim, P1075 and pinacidil appear to bind SUR2 at the intracellular loop
between TM13 and TM14, with two additional critical residues in TM17, SUR2-L1249 and
SUR2-T1253. These interactions have been confirmed by the observation that disruption to these
areas and/or residues alters the activating properties of the KCOs (Moreau et al., 2000; Uhde et
al., 1999). Diazoxide diverges structurally from that of the majority of KCOs, and its preferential
binding is thought to be at the NBFs (Shyng et al., 1997).
1.3.2.ii Sulfonylureas
A class of drugs called sulphonylureas also specifically binds the SUR subunit of KATP channels
but inhibit channel activity (Inagaki et al., 1996). Tolbutamide is an example of a first-generation
sulfonylurea that binds at TMD2 (Ashfield et al., 1999). Second and third generation, more
potent, sulfonylureas have been developed; an example is glibenclamide. The binding site of
glibenclamide also includes TMD2 with additional involvement of a site on the cytoplasmic loop
between TMD0 and TMD1 (Mikhailov et al., 2001). In general, sulfonylureas are most effective
at inhibiting SUR1-based channels, less so for SUR2B-, and least effective for SUR2A-based
channels.
1.4 KATP Channels in Tissue
The variation in nucleotide sensitivity, pharmacology and physiological pairings (Aguilar-Bryan
et al., 1995; Inagaki et al., 1996) of the Kir6.X and SURX subunits results in diversity of the
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properties and functional roles of KATP channels in the tissues in which they are expressed
(Akrouh et al., 2009; Nichols, 2006).
1.4.1 Tissue Distribution
RT-PCR data from a large variety of tissues indicates the pore-forming subunit Kir6.1 is very
widely expressed (Inagaki et al., 1995c). In contrast, Kir6.2 expression is prominent in pancreatic
beta cells, brain, heart and skeletal muscle(Inagaki et al., 1995a). In native tissues, SUR1
subunits only physiologically interact with Kir6.2. Consistent with this finding, SUR1 expression
is also in pancreatic beta cells, brain, and heart (Inagaki et al., 1995a). Conversely, the SUR2
subunits pair in native tissue with either Kir6.1 or Kir6.2. The splice variant SUR2A is found in
the heart and skeletal muscle where, based on electrophysiology studies, it pairs with Kir6.2.
Like Kir6.1, SUR2B subunits are expressed widely, and electrophysiological recordings from
KATP channels in vascular smooth muscle cells appear to reflect the co-assembly of SUR2B with
Kir6.1(Table 1.1) (Chutkow et al., 1996; Inagaki et al., 1995c).
1.4.2 Role in Tissue Function
1.4.2.i Brain
KATP channel expression and activity has been reported throughout the nervous system including
the pituitary gland, basal ganglia, cerebral cortex, hippocampus, basal forebrain, striatum, and
brain stem (Liss and Roeper, 2001; Seino and Miki, 2003; Yamada and Inagaki, 2005).
Electrophysiological characterization of KATP channel currents, combined with RT-PCR analysis
of KATP channel subunit expression, suggests composition of native channels in various regions
of the brain is quite heterogeneous. Based on radiolabeled glibenclamide studies, KATP channels
are most abundant in the hypothalamus and substantia nigra pars rectculata (SNr)neurons (Liss
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and Roeper, 2001; Seino and Miki, 2003; Yamada and Inagaki, 2005). The roles for KATP
channels in the brain will be discussed below in reference to these regions specifically.
Hypothalamus
The hypothalamus, which plays a critical role in glucose homeostasis by regulating counterregulatory hormones such as glucagon and catecholamines, relies on glucose-sensing neurons.
Within these neurons, the electrical firing patterns that lead to the autonomic input to release
glucagon and catecholamines are regulated by KATP channel activity (Miki et al., 2001).
Electrophysiological and RT-PCR analysis indicates that Kir6.2 and SUR1 compose the KATP
channels in these glucose-responsive neurons (Ashford et al., 1990; Miki et al., 2001; Spanswick
et al., 1997). As brain glucose levels drop, glucose-sensing neurons experience a decrease in the
intracellular ATP/ADP ratio that activates KATP channels, thereby hyperpolarizing the plasma
membrane and stimulating autonomic input for glucagon release (Figure 1.5). The release of
glucagon, from pancreatic alpha cells, stimulates gluconeogenesis and lipolysis to increase blood
glucose levels (Seino and Miki, 2003).
SNr
The basal ganglion contains SNr neurons, which are implicated in the propagation of seizures.
KATP channels are not active in SNr neurons at rest, allowing for active firing (Yamada and
Inagaki, 2005). In metabolically stressful conditions, such as hypoxia or hypoglycemia, the
activity of KATP channels is thought to be critical for protection from seizures. In metabolically
stressful conditions SNr neurons decrease ATP production, reducing the ATP/ADP ratio,
activating

KATP

channels

and

thereby

hyperpolarizing

the

membrane.

Membrane

hyperpolarization decreases the firing rate of SNr neurons inhibiting GABA release, which is
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Figure 1.5- The role of KATP channel activity in hypothalamic glucosesensing neuron function. Illustrated above is the role KATP channels play in
hypothalamic glucose-sensing neurons. The KATP channel is depicted in green
and the voltage gated Ca2+ channel is in orange.
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hypothesized to slow or prevent propagation (Figure 1.6)(Amoroso et al., 1990; Yamada et al.,
2001).
1.4.2.ii Pancreas
Within the pancreas there are clusters of endocrine cells called islets of Langerhans, of which
beta cells are the most abundant. Beta cells secrete insulin, an endocrine hormone which helps
decrease blood glucose levels. KATP channels are expressed abundantly on the plasma membrane
of beta cells, and are critical for regulating insulin release (Ashcroft and Gribble, 1999). During
or after a meal, as blood glucose levels elevate, beta cell metabolism increases, which elevates
the intracellular ATP/ADP ratio, inhibiting KATP channels. Inhibition of KATP channels leads to
membrane depolarization and activation of L-type Ca2+ channels, which increases Ca2+ entry.
The increased flux of calcium promotes fusion and release of insulin (Figure 1.7). Once in the
bloodstream insulin helps decrease blood glucose levels by facilitating glucose uptake into
muscle (Ashcroft and Gribble, 1999).
1.4.2.iii Heart
In the resting state, cardiomyocytes have elevated intracellular ATP/ADP ratios which leaves
KATP channels generally closed (Koster et al., 2001). While the role of KATP channels in
regulating heart rhythm or contraction is not fully understood, complete activation of KATP
channels in the heart can lead to profound shortening of the action potential (Figure 1.8)(Nichols
et al., 1991). During ischemia, in which a lack of oxygen or glucose disrupts the metabolic
function of cardiomyocytes, the ATP/ADP ratio decreases, activating KATP channels. Activation
of KATP channels under these conditions is thought to be cardio-protective since
hyperpolarization of the membrane will prevent excessive Ca2+ entry, thus preserving
cardiomyocyte function and promoting cell survival (Bers, 2008).
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Figure 1.6- Hypothesized role of KATP channels in SNr neuron function. Cartoon
of the potential role KATP channels play in SNr neurons. The KATP channel is depicted
in green, the voltage-gated Ca2+ channel is in orange, and yellow circles represent
GABA.
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Figure 1.7- The role of KATP channels in beta cell function. Cartoon of the
role KATP channels play in the pancreatic beta cell, where the KATP channel is
depicted in green, the voltage-gated Ca2+ channel is depicted in orange and
insulin is represented by purple circles.
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Figure 1.8- The role of KATP channels in cardiomyocyte function.
Cartoon of the role KATP channels play in cardiomyocytes, where the KATP
channel is depicted in green and the voltage gated Ca2+ channel is depicted
in orange.
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1.4.2.iv Skeletal Muscle
KATP channels are not thought to play a significant role in regulating the electrical activity of
skeletal muscle in the resting state, but may be crucial during muscle fatigue (Cifelli et al., 2008;
Gong et al., 2000). KATP channel activity can preserve a polarized membrane potential,
preventing voltage-dependent Ca2+ entry and decreasing contractility (Gong et al., 2000; Matar et
al., 2000). After treadmill or swim training, Kir6.2−/− mice, but WT, experience extensive fiber
damage in muscle. This observation is also consistent with KATP channel activation being
protective during fatigue (Kane et al., 2004; Thabet et al., 2005).
There is also evidence that KATP channels play a role in glucose uptake in skeletal
muscle: 1) sulfonylureas enhance glucose uptake into isolated skeletal muscle (Miki et al., 1998);
2) Kir6.2-/- mice have increased effectiveness of insulin in lowering blood glucose in the muscle
versus WT mice (Miki et al., 2002); and 3) muscle from SUR2-/- mice have enhanced insulinstimulated glucose transport in vitro compared to WT (Chutkow et al., 2001).
1.4.2.v Smooth Muscle
In smooth muscle cells, KATP channel activity is thought to be important for regulating vascular
tone (Chutkow et al., 2002; Miki et al., 2002). Excised patch clamp experiments on vascular
smooth muscle cells revealed KATP channels which did not spontaneously open in the absence of
ATP, a characteristic of nucleoside-dependent Kir6.1 channels (Beech et al., 1993; Kajioka et al.,
1991; Zhang and Bolton, 1996). It is hypothesized that these KATP channels help regulate tone by
activating in response to a declining ATP/ADP ratio or input from PKA pathways (Figure 1.4B).
Outward K+ currents through these channels hyperpolarize the membrane, thereby preventing
Ca2+-entry and leading to vasodilation of the vessel and decreases in contractility (Figure 1.9). In
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support of this proposed mechanism, treatment with the L-type Ca2+-channel inhibitor,
nifedipine, protects against the development of vasospasms in SUR2-/- animals (Chutkow et al.,
2002).
1.5 KATP Channels in Pathophysiology
KATP channels are widely expressed and provide a finely tuned link between metabolism and
electrical activity in tissues. Dysregulation of KATP channel activity (gain of function or loss of
function) results in pathophysiology. Several examples, in which KATP channel dysregulation
underlies a disease state, are described below.
1.5.1 Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
The first reported clinical characterization of a child with hypoglycemia that failed to improve
without treatment intervention occurred in 1956 (Cochrane et al., 1956). This disease was later
termed Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI), and is found in 1 of every
50,000 live births or up to 1 in every 3,000 live births in familial cases (Stanley and De León,
2012). Clinically, patients commonly present with increased plasma levels of insulin in
hypoglycemic conditions along with decreased levels of ketone bodies and free fatty acids
(Aguilar-Bryan and Bryan, 1999).
Mutations in KCNJ11 (Kir6.2) or ABCC8 (SUR1) account for nearly 70% of known
PHHI cases, with the majority of mutations found in ABCC8. Every PHHI-associated KCNJ11
(Kir6.2) or ABCC8 (SUR1) mutation leads to a decrease in KATP channel activity. This keeps the
beta cell membrane constantly depolarized and leads to elevated Ca2+ levels and secretion of
insulin (Figure 1.10)(Remedi and Koster, 2010).
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Figure 1.9- The role of KATP channels in smooth muscle cell
function. Cartoon of the role KATP channels play in smooth muscle
cell function, where the KATP channel is depicted in green and the
voltage gated Ca2+ channel is depicted in orange.
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There is no single mechanism by which all PHHI-associated KATP channel mutations reduce
channel activity. The mechanisms identified to date include trafficking defects, increased ATP
sensitivity, decreased MgADP activation and Kir6.2 inactivation(Denton and Jacobson, 2012).
Patients may be treated with the KATP channel opener diazoxide, or high doses of glucose to
maintain euglycemia (Pinney et al., 2008). However, in extreme cases in which these treatments
are ineffective, partial or complete removal of the pancreas is necessary(De Leon and Stanley,
2007).
1.5.2 Neonatal Diabetes Mellitus
Phenotypically the opposite of PHHI is a disease called Neonatal Diabetes Mellitus (NDM). Also
a condition commonly diagnosed in infants less than six months old, NDM patients present with
hyperglycemia and hypoinsulinemia. NDM incidence is estimated to be ~1 in every 100,000300,000 births (Naylor et al., 2011). It results from disruption in genes encoding critical proteins
for beta cell function including missense mutations in genes encoding proteins in the metabolic
pathway or involved in insulin production or secretion (Remedi and Nichols, 2009). The most
common monogenic cause of NDM is gain of function in KATP channel activity due to mutations
in either KCNJ11 (Kir6.2) or ABCC8 (SUR1) (Naylor et al., 2011). Despite elevated ATP/ADP
ratios, which results from increased glucose metabolism, the gain of function in KATP channel
activity prevents channel inhibition. Because KATP channels remain open, the membrane remains
hyperopolarized, leading to cessation of beta cell secretion of insulin (Figure 1.11) (Koster et al.,
2000).
NDM-associated KATP channel mutations are scattered throughout the Kir6.2 and SUR1
proteins (Denton and Jacobson, 2012), with multiple underlying molecular mechanisms. Kir6.2
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A

B

Figure 1.10- The role of KATP channels with decreased activity in the
function of beta cells in PHHI patients. Cartoon of the role KATP channels
play in normal beta cell function (A) or with decreased KATP channel activity
as found in PHHI patients (B). The KATP channel is depicted in green and
the voltage-gated Ca2+ channel is depicted in orange.
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mutations have most commonly been shown to give rise to increased channel activity by
increasing the intrinsic open probability of the channel or by decreasing the affinity or binding of
inhibitory ATP (Koster et al., 2008b). Similarly, mechanisms for SUR1 mutations also result in
overactive KATP channels, but enhanced affinity for MgADP and altered nucleotide hydrolysis at
the NBDs can additionally be responsible (Denton and Jacobson, 2012).
Originally NDM patients were treated with insulin injections as a means of managing
their blood glucose levels, but understanding the molecular basis of KATP channel-dependent
NDM cases has allowed for better/simpler treatment (Babenko et al., 2006; Sagen et al., 2004;
Zung et al., 2004). Now, instead of insulin injections, patients are typically administrated
sulphonylureas tablets orally, as an easier and more targeted treatment that directly inhibits the
overactive KATP channels. Additionally, sulfonylureas typically result in more regulated
glycemic control, relative to insulin therapy (Koster et al., 2008a). However, it should be noted
that in patients with mutations that result in extremely overactive KATP channels sulfonylureas
are not always effective (Remedi and Koster, 2010).
1.5.3 Cantu Syndrome
A disease more recently proposed to be associated with defective KATP channels is Cantu
Syndrome (CS), a rare and complex disorder. In the first description of this disorder, reported by
Dr. Cantu in 1982, four patients presented with hypertrichosis and dental abnormalities,
comparable to that seen in patients with hypertrichosis universalis and/or congenital
hypertrichosis lanuginose. Additional skeletal abnormalities in these patients establish CS as a
unique disorder (Cantu et al., 1982). The heritability of CS in both males and females from
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A

B

Figure 1.11- The role of overactive KATP channels in the beta cell function
of NDM patients. Cartoon of the role KATP channels play in normal beta
function (A) or the role of overactive KATP channels play in the beta cell
function of patients with NDM (B). The KATP channel is depicted in green and
the voltage-gated Ca2+ channel is depicted in orange.
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asymptomatic parents originally suggested that it can be an autosomal recessive disease (Cantu
et al., 1982). However, a familial case in which a father with CS passed it to his son, made
autosomal dominance more likely (Lazalde et al., 2000).
The number of CS patients described in the literature to date totals ~50 and the clinical
hallmarks have expanded to include: hypertrichosis, macrosomia, macrocephaly, coarse facial
appearance, cardiomegaly, and skeletal abnormalities (Nichols et al., 2013). Additional
symptoms present in subsets of patients includes patent ductus arteriosus, lymphedema, heart
vavular anomalies, and congenital hypertrophic cardiomyopathy (Grange et al., 2014). The fact
that hypertensive patients treated with (KCOs) such as Minoxidil (Mehta et al., 1975), diazoxide
(Goldberg, 1988), or pinacidil (Koblenzer and Baker, 1968) can develop similar features,
including hypertrichosis and structural defects in the heart, led to the hypothesis that CS could be
a result of dysregulated potassium channel activity (Grange et al., 2006).
It was not until 2012, however, when the genetic analysis of two separate CS patient
cohorts determined that the majority have mutations in ABCC9 (SUR2), that the K+ channel
dysregulation hypothesis was investigated. Harakalova et al. expressed Kir6.2-WT with three of
the identified SUR2 mutations and found that KATP channel activity was increased (Harakalova
et al., 2012). The data presented in the following chapters represent the first reports of KCNJ8
mutations which result in CS, and the mechanisms underlying the functional effects of these
mutations. Additionally included is the first molecular account and detailed mechanistic study of
how the gain of function in KATP channel activity arises from CS-associated SUR2 mutations.
KATP channels are highly regulated and are expressed throughout the body, and these
channels primarily function to link cell metabolism and cell excitability. This body of work is
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focused on determining the mechanism(s) by which identified mutations in Kir6.1 and SUR2,
found in CS-patients, alter KATP channel activity. CS patients with Kir6.1 or SUR2 mutations
have overlapping symptoms, and the results presented imply that the gain of function in KATP
channel activity is causal. This work underscores the intricate role KATP channels play in tissues
and how minor changes in channel activity can have profound effects on disease presentation.
Understanding the impact these mutations have on channel activity should provide insight into
how a gain of function in KATP channels activity results in the various pathophysiological
consequences of CS and, more importantly, guide future efforts focused on inhibiting these
overactive channels as a treatment option for patients.
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CHAPTER W: METHODS

Mutagenesis and Heterologous Expression of KATP Channels

The Quick Change II Site-Directed Mutagenesis kit (Agilent Technologies) was used to engineer
SUR2 mutations into ratSUR2A-pCMV6, Kir6.1 mutations into ratKir6.1-pcDNA3.1, and Kir6.2
mutations into mouseKir6.2-pcDNA3.1. Mutations were confirmed by direct sequencing of the
SUR2 or Kir6.X coding regions.

For channel expression, COSm6 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum, 105 units/L penicillin, and 100
mg/L streptomycin. At 60-70% confluence, cells were transfected with the relevant plasmids
using FuGENE6 transfection reagent (Promega). For experiments with homomeric CS mutant
channels, cells were co-transfected with pCDNA3.1‐mouseKir6.2-WT (0.6 µg) and wild-type
(WT) or mutant pCMV6-ratSUR2A (SUR2) (1 µg). For experiments on heteromeric channels,
cells were co-transfected with mouseKir6.2-WT, ratSUR2-WT, and mutant SUR2 at ratios of
0.6:0.5;0.5 (w:w:w). Cells transfected with GFP-pcDNA3.1 served as controls. A small amount
of GFP cDNA was included to allow for identification of GFP-expressing transfected cells
during electrophysiology experiments.
Macroscopic 86Rb+ Efflux Assays

Cells were incubated overnight at 37°C in DMEM containing 1 µCi/mL

86

RbCl (PerkinElmer

Life Sciences), and then incubated in Ringers solution (mM: NaCl 118, HEPES 10, NaHCO3 25,
KCl 4.7, KH2PO4 1.2, CaCl2 2.5, MgSO4 1.2, adjusted to pH 7.4 with NaOH) in (1) the absence
(basal) or (2) the presence of 2.5 mg/mL oligomycin and 1 mM 2‐deoxy‐d‐glucose (metabolic
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inhibition), (3) the presence of SUR1 or SUR2-specific K+ channel openers diazoxide or
pinacidil or (4) a combination of metabolic inhibition and pinacidil, to achieve maximal channel
activation. Subsequently, at selected time points (2.5, 5, 7.5, 15, 25, and 40 minutes), the solution
was collected and replaced with fresh solution. Upon completion of the assay, cells were lysed
with 2% SDS and collected, and the radioactive

86

Rb+ in these samples was measured.

86

Rb+

efflux is expressed as a fraction of total content. An inactivating, KATP-independent,
conductance was assumed to be present in all

86

Rb+ efflux experiments, and apparent rate

constants for the KATP-independent 86Rb+ efflux were obtained from GFP transfected cells using
the equation:

[1]

∗

Rb efflux = {1 −

∗

.

}

where k1 and k-1 are the apparent activation and inactivation rate constants. KATP-dependent 86Rb+
efflux was also assumed to activate and inactivate with time and was obtained using the
equation:

[2]

∗

Rb efflux = {1 −

∗

∗

∗

!.

}

where k1 and k-1 are the rate constants for KATP independent pathways (obtained from GFPtransfected cells by Equation 1), k2 and k-2 are the activation (k2) and inactivation (k-2) rate
constants for KATP-specific K+ conductance. k2 is then assumed to be proportional to the number
of active KATP channels.
86

Rb+ efflux experiments were also carried out in the presence of MI with the addition of

10 µM glibenclamide. In these experiments, the k-2 parameter was assumed to be the same for
each construct and all KATP-dependent fluxes were fitted simultaneously on any given day and
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under any given condition. To account for day-to-day variability, k1 was determined in mock
transfected cells for each condition (Basal, MI, PIN, MI+PIN, and MI+GLIB), and incorporated
into the equation to estimate the KATP-dependent k2 for each construct.

Excised Patch Clamp

After 24-48h, transfected cells that fluoresced green under UV light were selected for analysis by
excised patch clamp experiments at room temperature. For experiments, cells were placed in a
perfusion chamber that allowed for the rapid switching of solutions. Kint solution (mM: KCl 140,
HEPES 10, and EGTA 1, to pH 7.4) was used as the standard pipette (extracellular) and bath
(cytoplasmic) solution in these experiments. ATP or ADP was added as indicated. The
appropriate amounts of MgCl2 to be added in each Mg2+-nucleotide containing solution to attain
0.5 mM free Mg2+ were calculated by means of the CaBuf program (KU Leuven). Membrane
patches were voltage-clamped using an Axopatch 1D amplifier (Molecular Devices), and
currents were recorded at −50 mV (pipette voltage, +50 mV) in the on-cell and inside-out
excised patch configurations. Data were typically filtered at 1 kHz and digitized at 5 kHz with a
Digidata 1322A (Molecular Devices) A-D converter. pClamp and Axoscope software (Molecular
Devices) were used for data acquisition. For ATP inhibition, [ATP]-response relationships (Fig.
4) were fitted by equation 3:
[3]

"# $ = {1 + &

'()*+ /
,-

. }

0

where Irel (relative current) is the current in the presence of a given concentration of ATP relative
to current in zero ATP, Ki is the apparent ATP inhibition constant, and H is the Hill coefficient.
For PIP2 activation experiments, an ammonium salt of L-α-phosphatidylinositol-4,5bisphosphate from Porcine Brain (Brain PI(4,5)P2) (Avanti Polar Lipids) was dissolved in KINT
to make a 5 µg/µL working solution. For each patch, we estimated the relative Po by dividing the
maximum steady-state current in zero ATP by the maximum steady-state current in PIP2.
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CHAPTER Z: CANTU SYNDROME RESULTING FROM ACTIVATING MUTATION IN
THE KCNJ8 GENE
Cooper PE et al. 2014
3.1 Introduction
In collaboration with Heiko Reutter we screened KCNJ8 in an ABCC9 mutation-negative patient
who also exhibited clinical hallmarks of CS (hypertrichosis, macrosomia, macrocephaly, coarse
facial appearance, cardiomegaly, and skeletal abnormalities). A de novo missense mutation
encoding Kir6.1[Cys176Ser] was identified in the patient. Kir6.1[p.Cys176Ser] channels
exhibited markedly higher activity than wild-type channels, as a result of reduced ATP
sensitivity, whether co-expressed with SUR1 or SUR2A subunits. Our results identify a novel
causal gene in CS, and also demonstrate that the cardinal features of the disease result from gain
of KATP channel function, not from a Kir6-independent SUR2 function.
3.2 Methods
All genetic analysis and patient assessments were carried out in collaboration with
Heiko Reutter’s group.
3.3 Results
Case study
The clinical phenotype of the proband at the age of 3 months was originally described by Engels
et al. (Engels et al., 2002). Following the realization that this CS patient harbored a distinct
molecular basis, we have now carried out a detailed reevaluation of the patient at the age of 13
years. The patient shows key clinical hallmarks of CS, including congenital hypertrichosis,
macrosomia at birth, macrocephaly, coarse facial appearance, cardiomegaly, skeletal
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abnormalities, and developmental delay. At the time of reevaluation, he also had excessive
gingival hyperplasia (Figure 3.1C).
Echocardiography at 13 years of age showed normal biventricular function with signs of
noncompaction of the left ventricular apical myocardium, sonography of parenchymal abdominal
organs was within the normal range, as were ECG and 24 hr blood pressure measurements. The
patient's weight was 41 kg (25.–50. centile), height was 144 cm (10.–25. centile) and BMI was
19.5 (+0.3 SDS). He appeared disproportionate with a sitting height of 76 cm, arm span of
151.5 cm (10–25th centile) and arm span: height ratio >97th centile. His chest X-ray showed the
same broadening of ribs as initially reported (Engels et al., 2002). X-ray of his left hand showed
his bone age to be 10½ years at 13 years of age, corresponding to a delay of 2½ years.
Laboratory studies showed essentially undetectable serum IGF-1 levels (<25 ng/ml, Ref. value
131–690) and a relatively low IGFBP3 value of 1.4 μg/ml (Ref. value 2.6–8.9). Arginine
tolerance and clonidine test revealed absolute growth hormone (GH) deficiency (basal and all
stimulated GH concentrations were below 1.0 ng/ml). GHRH testing resulted in subnormal GH
secretion (max. GH 2.8 ng/ml).
Comparison of the present case with recently published CS patients carrying ABCC9
mutations (Harakalova et al., 2012; van Bon et al., 2012) shows that the present patient exhibits
all clinical hallmarks of CS, as well as 10/12 CS associated facial/cranial features; 2/5 cardiac
features; 7/17 skeletal abnormalities, visible on radiographic studies; and 3/15 additional
previously reported CS-associated features.
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Figure 3.1- Gain-of-function KCNJ8 mutation Kir6.1[Cys176Ser]underlies Cantu
syndrome. A: Sequence chromatogram of patient and unaffected parents’ genomic
DNA confirms de novo g.21,919,406A>T transition mutation in the patient, which is
absent in the mother and father. B: Ribbon diagram of two of the four Kir6.1 subunits
that form the K+-selective pore in KATP, based on the crystal structures of KirBac1.1
(PDB ID: 1BL8) and cytoplasmic domain of Kir3.1 (PDB ID: 1N9P). Shown are
Kir6.1 residues mutated in CS (Cys176Ser), and reported in association with the Jwave syndrome (p.Ser422Leu).C: Clinical phenotype of the patient. Photographs of
the patient at 13 years reveal extensive hypertrichosis, macrocephaly, coarse facial
appearance, long arm- and torso-to-height ratio, and gingival hyperplasia with
thickened lips.
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Genetic analysis
To date, mutations in ABCC9 are the only known genetic cause of CS (Czeschik et al., 2013;
Harakalova et al., 2012; van Bon et al., 2012). In our initial study, we found that nine out of 12
patients diagnosed with CS carry missense mutations in ABCC9 (van Bon et al., 2012).We
performed Sanger sequencing of the three coding exons of KCNJ8 in the three unexplained
patients, including the present case. KCNJ8 was chosen as the most promising candidate gene
because of the functional considerations stated above. The study was approved by the local
ethics committees, and all participating patients gave written informed consent. Parental consent
was given on behalf of patients younger than 18 years of age; the study was explained to children
capable of giving assent, and they provided oral assent.
In

the

proband,

we

identified

a

mutation

Chr12(GRCh37):g.21919406A>T

(NM_004982.2:c.526T>A), in the KCNJ8 gene, encoding a missense mutation (Cys176Ser) in
the Kir6.1 protein (Figure 3.1).We did not observe the mutation in any of 2,096 in-house
exomes, nor is it reported in any of 6,503 individuals from the exome variant server (Exome
Variant

Server,

NHLBI

GO

Exome

Sequencing

Project

(ESP),

Seattle,

WA

(URL: http://evs.gs.washington.edu/EVS/) [March 2014]). The variant has been deposited in the
LOVD 3.0 (http://databases.lovd.nl/). The mutation is predicted to be “deleterious” by SIFT
(score 0.03), and probably damaging by PolyPhen2 (score 1.0). The affected amino acid is fully
conserved in both mammalian Kir6.1 and Kir6.2 proteins, suggesting a key role in channel
function. Paternity was proven and sample mix-up excluded by STR marker analysis. The
mutation was not present in maternal or paternal DNA and hence was presumed to have arisen de
novo. Primer sequences and PCR conditions are available upon request.
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Functional analysis of KCNJ8 mutations
To assess the effect of the Cys176Ser mutation on channel activity, mutant and wild type KCNJ8
(Kir6.1) cDNAs were co-transfected with ABCC8 (SUR1) or ABCC9 (SUR2A) cDNAs. Channel
activity was assessed under normal metabolic conditions, in metabolically inhibited conditions
(mimicking tissue ischemia), and in the presence of pharmacological potassium channel openers
(KCOs), using

86

Rb+ efflux assays (see Methods). We also examined the channel activity

resulting from Kir6.1[Ser422Leu], a mutation reported in several studies to be associated with Jwave abnormalities in the electrocardiogram (Barajas-Martinez et al., 2012; Medeiros-Domingo
et al., 2010). As shown in Figure 3.2 and 3.3, very similar fluxes were measured for WT Kir6.1
and Ser422Leu channels. Measurable basal conductance was present for WT Kir6.1 with SUR1,
but only MI- or KCO-stimulated fluxes were present for WT plus SUR2A. In contrast,
significant fluxes were present for Kir6.1[Cys176Ser] with SUR1, and both MI- and KCOstimulated fluxes were higher for each Kir6.1[Cys176Ser]/SUR combination. These experiments
establish that the Cys176Ser mutation indeed causes a gain- of-function in the Kir6.1 channel,
leading to markedly enhanced channel activity even under basal metabolic conditions, in coexpression with either SUR1 or SUR2A subunits.
To gain further insight to the mechanism by which the mutation enhances channel
activity, we turned to patch-clamp experiments. The majority of KATP channels in vivo are
probably formed as homomeric Kir6.1 tetramers or Kir6.2 tetramers, although there is evidence
that heteromeric Kir6.1/Kir6.2 combinations may also be present in cardiac (Bao et al., 2011)
and smooth (Flagg et al., 2010; Insuk et al., 2003) muscle, for instance. Since the original
cloning and expression of KATP subunit genes, it has been clear that Kir6.1 channels are
experimentally considerably more labile in excised patches than are Kir6.2 channels, and channel
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Figure 3.2- Increased channel activity in basal and stimulated conditions in intact cells
expressing Kir6.1[C176S]-containing KATP channels. Relative efflux of 86Rb+ as a
function of time in basal conditions (left), in the presence of potassium channel openers
(center), or in metabolic inhibition (right) for reconstituted wild-type and mutant KATP
channels (with SUR1 (above) or SUR2A (below)), and untransfected controls (mean +
s.e.m., from 4-6 experiments). Data were fit with a double-exponential equation to obtain
rate constants for KATP-dependent efflux, k2 (see Methods). Lines show mean fitted equations
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Figure 3.3- Increased relative efflux in basal and stimulated conditions in
intact cells expressing Kir6.1[C176S]-containing KATP channels. Relative
efflux rate constants for KATP-dependent 86Rb+efflux (k2)of 86Rb+ as a function of
time in basal conditions (black), in the presence of potassium channel openers
(white), or in metabolic inhibition (gray) for reconstituted wild-type and mutant
KATP channels (with SUR1 (A) or SUR2A (B)), and untransfected controls in
basal conditions relative to metabolic inhibition (MI) for WT and mutant
KATP channels (mean ± s.e.m., from 4 to 6 experiments). *P < 0.01 compared
with the wild-type KATP by unpaired Student's t-test.
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activity rapidly runs down in the absence of Mg-nucleotides, complicating the assessment of
both inhibitory nucleotide sensitivity and intrinsic open probability of the channel. In the patient,
the mutation is present in only one allele and since the active channels are tetramers, expressed
KATP channels in native cells will therefore be expected to consist of a mixture of both
Cys176Ser and wild-type Kir6.1 or Kir6.2 subunits. To take advantage of this fact and
additionally test the effect of heterozygosity, we co-expressed a 1:1 mixture of wild-type or
mutant Kir6.1 cDNAs with wild-type Kir6.2 and SUR2A cDNAs (Figure 3.4).
These mixtures generated measurable fluxes in tracer studies and stable currents in
excised patches. From these measurements it is evident that enhanced channel activity in intact
cells expressing Cys176Ser (Figure 3.4) result from reduced ATP sensitivity (Figure 3.5B and
3.5C). We cannot formally rule out the possibility that altered trafficking and increased plasma
membrane channel density may also play a role, but such effects have not previously been
described for mutations in Kir channel pore regions. The findings indicate that the heterozygous
Cys176Ser mutation in Kir6.1 will over activate any native KATP channels in which it is present.
The results are very consistent with the effects of the exact equivalent, and well-studied
mutation, Cys166Ser in Kir6.2, which reduces ATP sensitivity of expressed channels by ∼50fold (Loussouarn et al., 2000; Tucker et al., 1998). Additional mutations at this residue in Kir6.2,
which also cause marked GOF, have been identified as causal in the most severe form of
neonatal diabetes that is associated with developmental delay and epilepsy (Gloyn et al., 2006).
3.3 Discussion
CS was first characterized as such by J.M. Cantú in 1982 (Cantu et al., 1982). A genetic cause
was recently reported (Harakalova et al., 2012; van Bon et al., 2012), with coding mutations
identified in the ABCC9 gene, in 25 out of 30 patients. The present study reveals that a
heterozygous mutation in KCNJ8, encoding the Kir6.1 pore-forming subunit of KATP channels,
can also cause CS. A recent study identified a different mutation in KCNJ8 (encoding Val65Met)
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Figure 3.4- Increased channel activity in basal and stimulated conditions in
reconstituted heteromeric KATP channels containing Cys176Ser subunits.
A) Relative efflux of 86Rb+ as a function of time in basal conditions (left), in the
presence of potassium channel openers (center), or in metabolic inhibition (right) for
heteromeric Kir6.1/Kir6.2 or Kir6.1[Cys176Ser]/Kir6.2 plus SUR2A KATP channelexpressing cells, and untransfected control cells (mean + s.e.m., from 3 experiments).
Data were fit with a double-exponential equation to obtain rate constants for KATPdependent efflux, k2 (see Methods). Lines show mean fitted equations. B) Rate
constants for KATP-dependent 86Rb+ efflux (k2) in basal conditions (black) and in
metabolic inhibition (MI) (gray) from COS cells expressing heteromeric Kir6.1/Kir6.2
or Kir6.1[Cys176Ser] (C176S)/Kir6.2 plus SUR2A KATP channels.
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Figure 3.5- Reduced ATP-sensitivity of reconstituted heteromeric KATP channels
containing
Kir6.1[Cys176Ser]
subunits. A:
Rate
constants
for
KATPdependent86Rb+ efflux (k2) in basal conditions and in metabolic inhibition (MI) from COS
cells expressing heteromeric Kir6.1/Kir6.2 or Kir6.1[Cys176Ser] (C176S)/Kir6.2 plus
SUR2A KATP channels. B: Representative currents recorded from inside-out membrane
patches from COS cells expressing heteromeric Kir6.1/Kir6.2 or Kir6.1[Cys176Ser]
(C176S)/Kir6.2 plus SUR2A KATP channels at −50 mV in Kint solution (see Supplementary
information). Patches were exposed to differing [ATP] and baseline current was determined
by exposure to 5 mM ATP. C: Steady-state dependence of membrane current on [ATP]
(relative to current in zero ATP (Irel)) for wild-type and Cys176Ser-containing channels.
Data points represent the mean ± s.e.m. (n = 6–8 patches). The fitted lines correspond to
least squares fits of a Hill equation. *P < 0.01 compared with the wild-type KATP by
unpaired Student's t-test.
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in another CS patient (Brownstein et al., 2013), although there was no functional characterization
of mutant channels. The marked GOF in expressed Kir6.1[Cys176Ser] channels (Figures 3.1
and 3.2), which mirrors the well-studied properties of Kir6.2 channels with mutations at the
equivalent Cys166 residue (Gloyn et al., 2006; Loussouarn et al., 2000; Trapp et al., 1998;
Tucker et al., 1998), clearly establishes Cys176Ser as a severe GOF. Thus GOF mutations in
both ABCC9 and KCNJ8 cause essentially the same hallmark CS features in the affected patients
indicating that these features all result from GOF of KATP channels formed from these subunits.
This is a subtle but critical conclusion: previous studies (Aggarwal et al., 2010; Stoller et al.,
2010) have raised the possibility of Kir6-independent roles of SUR2 proteins and, in the absence
of the present findings, some or all of the features of CS could conceivably have arisen from
non-channel functions of the SUR2 protein.
The results underscore the key role of KATP channels in coupling cell membrane potential
with diverse tissue functions. Our results are consistent with the finding that vascular smooth
muscle contractility is markedly decreased in the presence of KATP channel openers (Flagg et al.,
2010) and in transgenic mice expressing mutant Kir6.1 subunits with reduced sensitivity to
inhibitory ATP (Li et al., 2013). These observations potentially explain some of the key findings
in CS, including patent ductus arteriosus, as was present in the patient reported here.
A novel finding is the puzzling combination of biochemical signs of absolute growth
hormone (GH) deficiency, yet postnatal growth with height within the normal range. Pituitary
GH secretion is mainly regulated by two hypothalamic neuropeptides. GHRH stimulates GH
release, whereas somatostatin inhibits GH secretion (Muller et al., 1999). In addition, a number
of GH-releasing peptides are able to modulate GH release. The rat pituitary expresses several Kir
channel alpha-subunits, including Kir6.1 (Wulfsen et al., 2000). GHRP-2, one member of the
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GH-releasing neuropeptides, exerts its GH secretory effect through a reduction in potassium
current (Xu et al., 2002). It is therefore tempting to speculate that GOF mutations in pituitary
KATP channels exert an opposite effect on GHRH stimulation, leading to resistance to
hypothalamic induction of GH release. On the other hand, GH insufficiency yet normal growth
can only be explained by a concurrent stimulation of long bone growth. Previous animal models
indicated that a significant part of postnatal growth depends on local growth stimulation in the
growth plate rather than on the effect of circulating IGF-1 (Ohlsson et al., 2009; Yakar et al.,
1999), although understanding of molecular mechanisms at the growth plate leading to long bone
growth is incomplete. It is not yet clear whether ABCC9 mutation patients exhibit similar
deficiencies, and if not, this finding may be a KCNJ8-specific outcome, or may be unrelated to
CS.
A common KATP pathway can account for direct overlap of CS features resulting from
mutations in ABCC9 and KCNJ8, as well as with features resulting from overexposure to
minoxidil and other KATP channel openers (Avatapalle et al., 2012; Kaler et al., 1987; Nguyen
and Marks, 2003; Shanti et al., 2009). However, this does not provide an obvious explanation for
many CS features. For instance, macrocephaly and characteristic facial features, as well as
skeletal abnormalities are present in both ABCC9 and KCNJ8 patients. However, while KATP
channels generated by these subunits have been reported in human chondrocytes (Mobasheri et
al., 2012; Rufino et al., 2013) and osteoblasts (Kawase et al., 1996), their role in maturation and
proliferation remains unknown, and the cellular pathway involved is not obvious. Interestingly,
minoxidil has been reported to induce pseudoacromegalic features in the absence of elevated GH
or IGF-1 (Nguyen and Marks, 2003). Similarly, epicanthal folds and deep plantar creases might
result from KATP gain-of-function, but the underlying cause is unknown. Finally, pericardial
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effusion, polydramnios and lymphoedemia, potentially all related problems of membrane barrier
breakdown, are unexplained. SUR2/Kir6.1 KATP channels have been reported in epithelial cells
(Bardou et al., 2009), but again, cellular pathways are unexplained.
Finally, we would note that several other studies have reported a different mutation
(p.Ser422Leu) in the Kir6.1 protein to be associated with ‘early repolarization syndrome’ (ERS),
characterized by abnormalities in the J-point of the electrocardiogram (Delaney et al., 2012;
Haissaguerre et al., 2009). Recent studies have reported that this p.Ser422Leu mutation enhances
channel activity (Medeiros-Domingo et al., 2010), by reducing ATP-sensitivity (BarajasMartinez et al., 2012). If so, there is a clear inconsistency: neither J-wave abnormalities nor other
arrhythmias have been reported in CS patients, and none of the CS features have yet been
reported for ERS patients. Our own data (Figure 3.2) indicate that, in recombinant COS cells,
p.Ser422Leu does not affect Kir6.1-dependent KATP channel activity, consistent with the recent
recognition that this mutation may actually represent a common variant (~4%) in Ashkenazim
subjects, and not clearly associated with ERS (Veeramah et al., 2014).
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CHAPTER f: DISEASE CAUSING SLIDE HELIX RESIDUE MUTATION IN KIR6.1 AND
KIR6.2
4.1 Introduction
While all previous reports of CS-associated mutations are in the ABCC9 gene, a CS patient with
a KCNJ8 mutation, encoding V64M in the Kir6.1 subunit, was described by Brownstein et al. in
2013, although no functional support for this mutation causing any change in channel activity
was provided. Interestingly, a previously identified mutation at the equivalent position in Kir6.2
(V64L), was reported to have no effect on KATP channel a. Here, I directly compare these two
published mutations: valine to methionine and valine to leucine in the equivalent positions in
Kir6.1 (V65) and Kir6.2 (V64), co-expressed with SUR1 or SUR2A. Using macroscopic
rubidium (86Rb+) efflux assays, I show that, compared to WT channels, both Kir6.1-V65M and
Kir6.2-V64M enhance KATP activity, but channels formed with Kir6.1-V65L and Kir6.2-V64L
are unaffected. Additionally, Kir6.2-V64M-based channels decrease ATP sensitivity and PIP2
activation, but V64L-based channels do not. Taken together, these data provide functional
support for the notion that CS-associated Kir6.1-V65M mutation leads to overactive KATP
channels. More specifically, the mechanism of this GOF is a result of the valine-to-methionine
substitution increasing channel Po and thereby indirectly decreasing ATP inhibition. These
findings are consistent with a causal involvement of this mutation in CS.
4.2 Results
Kir6.1-V65M, but not Kir6.1-V65L, forms overactive KATP channels paired with SUR1 or SUR2
To examine KATP channel activity in intact cells, I performed rubidium (86Rb+) efflux assays (see
Methods) under three metabolic conditions: basal; metabolic inhibition (MI), which prevents
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ATP production; or in the presence of SURX-specific potassium channel openers diazoxide
(SUR1) or pinacidil (SUR2). Kir6.1-WT, Kir6.1-V65M and Kir6.1-V65L were each
homomerically expressed with SUR1 (Figure 4.1). Under basal and diazoxide conditions Kir6.1V65M based channels exhibited significantly higher 86Rb+ efflux rate compared to WT channels,
while Kir6.1-V65L channels efflux rates were comparable to WT (Figures 4.1A and 4.1B).
Maximal activation, estimated under MI conditions, comparable for Kir6.1-V65M, V65L and
Kir6.1-WT based channels, implying no differences in expressed channel densities (Figure
4.1C).
When paired with SUR2A, basal fluxes through Kir6.1-WT, Kir6.1-V65M and Kir6.1-V65L
were undistinguishable (Figure 4.2A), presumably due to lower activation of SUR2 by MgATP
or MgADP compared to SUR1(Masia et al., 2005). However, when KATP- specific fluxes were
activated in pinacidil or MI conditions, Kir6.1-V65M but not Kir6.1-V65L fluxes were
significantly increased compared to WT channels (Figure 4.2B and 4.2C). These trends are
consistent with Kir6.1-V65M causing a GOF, but Kir6.1-V65L having WT-level KATP channel
activity when paired with SUR1 or SUR2 (Figures 4.1 and 4.2).
Kir6.2-V64 mutated to methionine or leucine produces comparable functional changes to Kir6.1V65M or L mutations
Kir6.1 (V65) and Kir6.2 (V64) are localized within an identical sequence region in the slide
helix (Inagaki et al., 1995c). Therefore, it is likely the role this valine residue plays in gating is
conserved between each channel. In the basal condition, whether expressed with SUR1 or SUR2,
Kir6.2-V64M formed channels with increased efflux rates compared to wild type channels, but
Kir6.2-V64L-based channels exhibited comparable activity to WT (Figure 4.3A and 4.4A).
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Figure 4.1- Homomeric Kir6.1-V65M–but not Kir6.1-V65L–expressed with SUR1
increases KATP channel activity under basal conditions and in the presence of diazoxide
in intact cells. Cumulative 86Rb+ efflux, as a function of time, was measured in GFPtransfected control cells (black symbols), and in cells transiently expressing SUR1 plus
Kir6.1-WT (white triangles), Kir6.1-V65M (blue squares) or Kir6.1-V65L (light grey
circles). Experiments were done in basal conditions (A), in the presence of the K+ channel
opener diazoxide (B), or metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (C).
The data represents the means + S.E.M. of 8-18 experiments. Flux data from each condition
was fit with a double-exponential equation to obtain the rate constants for KATP-dependent
efflux, k2, where lines show mean fitted relationships. Graphical representation of the
determined k2 rate constants are shown on the right of the corresponding cumulative efflux
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over time. *p< 0.05 as compared to WT (unpaired Student’s t test).

Figure 4.2- Homomeric Kir6.1-V65M (but not Kir6.1-V65L) expressed with SUR2A
increases KATP channel activity under Metabolic Inhibition (MI) and in the presence of
pinacidil in intact cells. Cumulative 86Rb+ efflux, as a function of time, was measured in GFPtransfected control cells (black symbols), and in cells transiently expressing SUR2A with Kir6.1WT (white triangles), Kir6.1-V65M (blue squares) or Kir6.1-V65L (light grey circles).
Experiments were done under basal conditions (A), in the presence of the K+ channel opener
pinacidil (B), or metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (C). The data
represents the means + S.E.M. of 3 experiments. Flux data from each condition was fit with a
double-exponential equation to obtain the rate constants for KATP-dependent efflux, k2 (right),
where lines show mean fitted relationships. Graphical representation of the determined k2 rate
constants are shown on the right of the corresponding cumulative efflux over time. * p< 0.05 as
compared to WT (unpaired Student’s t test).
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Figure 4.3- Homomeric Kir6.2-V64M–but not Kir6.2-V64L– expressed with SUR1
increases KATP channel activity in basal conditions and in the presence of Diazoxide in
intact cells. The cumulative 86Rb+ efflux, as a function of time, was measured in GFPtransfected control cells (black symbols), and in cells transiently expressing SUR1 with Kir6.2WT (white triangles), Kir6.2-V64M (navy squares) or Kir6.2-V64L (dark grey circles).
Experiments were done in basal conditions (A), in the presence of the K+ channel opener
diazoxide (B), or metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (C). The data
represents the means + S.E.M. of 3-5 experiments. Flux data from each condition was fit with a
double-exponential equation to obtain the rate constants for KATP-dependent efflux, k2 (right),
where lines show mean fitted relationships. Graphical representation of the determined k2 rate
constants are shown on the right of the corresponding cumulative efflux over time. * p< 0.05 as
compared to WT (unpaired Student’s t test).
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Figure 4.4- Homomeric Kir6.2-V64M–but not Kir6.2-V64L–with SUR2A
increases KATP channel activity in basal conditions and in the presence of pinacidil
in intact cells. The cumulative 86Rb+ efflux, as a function of time, was measured in
GFP-transfected control cells (black symbols), and in cells transiently expressing
SUR2A with Kir6.2-WT (white triangles), Kir6.2-V64M (navy squares) or Kir6.2V64L (dark grey circles). Experiments were done in basal conditions (A), in the
presence of the K+ channel opener pinacidil (B), or metabolic inhibitors (MI)
oligomycin and 2-deoxy-d-glucose (C). The data represents the means + S.E.M. of 3-6
experiments. Flux data from each condition was fit with a double-exponential equation
to obtain the rate constants for KATP-dependent efflux, k2 (right), where lines show
mean fitted relationships. Graphical representation of the determined k2 rate constants
are shown on the right of the corresponding cumulative efflux over time. * p< 0.05 as
compared to WT (unpaired Student’s t test).
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These trends were also seen in the presence of diazoxide or pinacidil (Figure 4.3B and 4.4B). In
MI Kir6.2 WT, Kir6.2-V64M and Kir6.2-V64L reached the same maximum with comparable
efflux rates, whether paired with SUR1 or SUR2, indicating that these mutations do not alter the
expression of KATP channels (Figure 4.3C and 4.4C). Overall, compared to WT channels, the
valine-to-methionine substitution in both Kir6.1 and Kir6.2 results in a gain of function in KATP
activity, but the valine-to-leucine mutation exhibits comparable channel activity (Figures 4.14.4).
Kir6.2-V64M overactivity results from decreased ATP sensitivity
The 86Rb+ efflux experiments demonstrate that the behavior of valine-to-methionine and valineto-leucine substitutions are consistent whether expressed in Kir6.1 or Kir6.2, but do not reveal
underlying molecular mechanism(s). Unlike Kir6.2, Kir6.1-based channels quickly run down and
require activatory nucleotides to maintain channel activity, making assessment of nucleotide
sensitivity experimentally challenging (Babenko et al., 2000). To assess the details of increased
channel activity, inside-out excised patch-clamp experiments on Kir6.2-WT-, Kir6.2-V64M- and
V64L-based channels paired with SUR2A were carried out. Intrinsic sensitivity to ATP
inhibition (in zero Mg2+) was similar for WT (Ki = 25 μM) and Kir6.2-V64L (Ki = 16 μM)
channels. However, KATP channels expressing Kir6.2-V64M exhibited a significant right shift in
the [ATP]-response (Ki = 289 μM) (Fig. 4.5B). A decreased sensitivity to intracellular ATP
could account for the increased activity of KATP channels under basal conditions in the intact cell
(Figure 4.4A). PIP2 potentiation experiments were carried out on wild type and Kir6.2-V64Mbased channels to assess ATP-independent open state stability (Enkvetchakul and Nichols, 2003)
(Figure 4.6B). As seen in Figure 4.6C, wild type channels have a relative open probability of
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Figure 4.5- Gain of function in Kir6.2-V64M due to decreased ATP-sensitivity.
Representative excised patch current recordings from COSm6 cells co-expressing SUR2AWT with Kir6.2-WT, Kir6.2-V64M or Kir6.2-V64L (A). Membrane potential was held at 50mV, and currents were recorded continuously on-cell and in inside-out excised patches
exposed to KINT in the absence or in the presence of 0.01, 0.1 or 1 mM ATP. Doseresponse data (mean ± SEM 10 patches each) were fit to equation 1 to estimate the ATP
concentration for half-maximal inhibition Ki: WT (24.7 µM), Kir6.2-V64M (16 µM), and
Kir6.2-V64L (289.3 µM) (B).
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Figure 4.6- Increased open state stability in Kir6.2-V64M-based channels underlies decreased
ATP sensitivity. Representative KATP current traces for SUR2A-WT expressed with Kir6.2-WT (A)
or Kir6.2-V64M (B) following excision and in the presence of 10 mM ATP, 1mM ATP, or 5 µg/µLPIP2. The relative Po for individual patches from WT (white diamonds) and V64M (navy blue
squares) was determined as a ratio of the maximum steady-state current upon excision, in the absence
of nucleotides, over the maximum current measured in PIP2. The average Po (black bars) is the mean
of 8 individual patches for each construct ± SEM. The relative Po for WT channels is 0.73 ± 0.08
(WT) and 1.05 ± 0.07 for Kir6.2-V64Mbased channels. *p< 0.05 as compared to WT (unpaired
Student’s t test).
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0.73±0.08 where as Kir6.2-V64M channels have a significantly increased Po of 1.05±0.07,
indicating that the valine-to-methionine substitutions also affect channel PO.
4.3 Discussion
Cantu Syndrome, a complex multi-organ disease, was first described in 1982(Cantu et al.,
1982). Recently, several studies have demonstrated that the majority of CS patients have
a mutation in ABCC9 (Harakalova et al., 2012; van Bon et al., 2012). In addition, two patients
with clinically defined CS have been identified with coding mutations in KCNJ8 (Brownstein et
al., 2013; Cooper et al., 2014), and two of these studies, together with the present study, confirm
that the disease therefore results from gain of function in KATP channel activity that is generated
by the SUR2 and Kir6.1 subunits encoded by these genes.
Effects of equivalent residue mutations on KATP channel activity
In a previously reported case of neonatal diabetes, a mutation at the equivalent position in Kir6.2
(V64L) was reported along with an additional mutation at F60Y. When these mutations were
expressed separately and channel activity was assessed, Kir6.2-V64L was determined to have no

effect on KATP activity, and GOF in KATP activity was solely a result of the increased KATP
channel activity from the F60Y mutation (Mannikko et al., 2009). Similarly, Kir6.2-V64A does
not perturb KATP activity (Li et al., 2013). In the present study I have confirmed this finding, and
shown that mutation of the equivalent valine to leucine in either Kir6.1 or Kir6.2 is without
effect on recombinant channel activity. Conversely, mutation to methionine in either Kir6.1 or
Kir6.2 generates a net gain of function. The inability of either leucine or alanine substitutions at
this position to alter KATP activity might suggest that the bulkiness of the mutated residue at this
position is relevant to if and how it alters KATP channel activity.
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Mechanism of increased KATP channel activity through Kir6.1-V65M and Kir6.2-V64M-based
channels
Given the experimental difficulty of recording Kir6.1/SUR2 currents (Cooper et al., 2014),
Kir6.2-V64M and V64L were instead paired with SUR2A to determine nucleotide sensitivity of
KATP channels formed with each mutation. In excised patches, the ATP-sensitivity of Kir6.2V64M based channels, but not Kir6.2-V64L, was significantly reduced, compared to Kir6.2-WT
channels. This result is consistent with the overall gain of function in channel activity in Kir6.2V64M and Kir6.1-V65M being a result of decreased ATP-sensitivity (Figure 4.5). As has
previously been described, mutations in Kir6.2 can reduce ATP sensitivity by two distinct
mechanisms: 1) by directly altering ATP binding and/or 2) by increasing ATP-independent open
probability, thus indirectly reducing ATP sensitivity (Koster et al., 2008a). By measuring the
relative PIP2 activation of Kir6.2-V64M compared to Kir6.2-WT-based channels, we have
shown that the Po is increased in the absence of ATP (Figure 4.6). This result is consistent with
this mutation lying outside the ATP binding pocket, and thereby altering ATP sensitivity
indirectly.
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CHAPTER g: DIFFERENTIAL MECHANISMS OF CANTU SYNDROME-ASSOCIATED
GAIN-OF-FUNCTION MUTATIONS IN THE ABCC9 (SUR2) SUBUNIT OF THE KATP
CHANNEL
5.1 Introduction
The functional consequences of multiple uncharacterized CS-mutations remain unclear. In this
paper, we have focused on determining the functional consequences of 3 documented human CSassociated ABCC9 mutations: human P432L, A478V and C1043Y. The mutations were
engineered in the equivalent position in rat SUR2A (P429L, A475V and C1039Y) and each was
co-expressed with mouse Kir6.2. Using macroscopic rubidium (86Rb+) efflux experiments, we
show that KATP channels formed with P429L, A475V or C1039Y mutants enhance KATP activity
compared to WT channels. We used inside-out patch-clamp electrophysiology to measure
channel sensitivity to ATP-inhibition and MgADP-activation. For P429L and A475V mutants,
sensitivity to ATP inhibition was comparable to WT channels, but activation by MgADP was
significantly greater. C1039Y-dependent channels were significantly less sensitive to inhibition
by ATP or by glibenclamide, but MgADP activation was comparable to WT. The results indicate
that these three Cantu Syndrome mutations all lead to overactive KATP channels, but at least two
mechanisms underlie the observed gain of function: decreased ATP inhibition and enhanced
MgADP activation.
5.2 Methods
All rubidium efflux experiments were done by Monica Sala-Rabanal. Sequence alignment and
homology model by Sun Joo Lee.
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Homology Modeling
Models of human SUR2A (Figure 5.1) were built using Modeller v9.8 from the template of the
multidrug ABC transporter Sav1866 (2ONJ, to model the ‘open’ conformation) and
heterodimeric ABC transporter TM287-TM288 (3QF4, to model the ‘closed’ conformation). The
TM0 domain and L0 loop (1-281) were omitted due to lack of sequence homology to any
proteins of known structure. Two extended loops unique to SUR2A were also omitted: one
connecting TM1 and NBD1 (614-672) and a second connecting NBD1 and TM2 (920-966). A
multiple sequence alignment (MSA) was carried out using ClustalW2 between SUR2 and the
two template sequences. Due to low sequence identity, other proteins in the human ABCC family
(ABCC1, 2, 3, 4, 5, 6, 8 and 10) were included in the alignment for TM1 and NBD1. Highly
conserved sequence identity enabled a reliable sequence alignment of TMD2 and NBD2 by
MSA between SUR2 and SUR1, 2ONJ, and 3QF4.
5.3 Results
Homomeric mutant channels are overactive in various metabolic conditions
Cantu syndrome-associated mutations have been found throughout the coding sequence (Figure
5.1). For the present study, we focused on two previously unexamined mutations (human P432L
and C1043Y, corresponding to rat P429L and C1039Y, respectively), located in the TMD1 and
TMD2 segments, and A478 (corresponding to rat A475V), also located in the TMD1 region. To
examine KATP channel activity in intact cells, we performed 86Rb+ efflux experiments under four
different conditions: basal; metabolic inhibition (MI); in the presence of pinacidil (PIN); and MI
and pinacidil combined (MI + PIN). As shown in Figures 5.2 and 5.3, homomeric expression of
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Figure 5.1- Cantu Syndrome mutations in SUR2 Alignment of SUR2 (ABCC9) with the
multidrug ABC transporter Sav1866 (2ONJ) and heterodimeric ABC transporter TM287-TM288
(3QF4), upon which we built homology models. Key structural domains TMD1,2 and NBD1,2)
are indicated, as well as predicted alpha helical (pink) and beta strand (green) segments (A).
Homology models of ‘open’ (B) and ‘closed’ (C) conformations of the SUR2A protein, which are
based on Staphylococcus aureus Sav1866, a bacterial homolog of the human ABC transporter
Mdr1 and hetero-dimeric ABC transporter TM287-TM288 (TM287/288) from Thermotoga
maritime, respectively. Published CS mutations from previous reports are shown in green (open)
and light pink (closed).
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Figure 5.2- Increased channel activity in intact cells expressing homomeric P429L, A475V or
C1039Y-containing KATP channels. 86Rb+ efflux, as a function of time, was measured in GFPtransfected control cells (dashed), and in cells transiently expressing reconstituted Kir6.2-based KATP
channels with WT, P429L, A475V or C1039Y SUR2 subunits in homomeric configuration, in basal
conditions (A), in the presence of metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (B), or in
the K+ channel opener pinacidil (C), or in the presence of both MI and pinacidil (D). The data represent
means + S.E.M. of 6-10 experiments. Flux data were fit with equation 1 (GFP) to obtain the rate
constant k1 or equation 2 to obtain the rate constants for KATP-dependent efflux, k2 (Figure 5.3), where
lines show mean fitted relationships.
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Figure 5.3- KATP conductance is increased in basal and stimulated conditions in
intact cells expressing homomeric P429L and A475V-based KATP channels. Rate
constants for KATP-dependent 86Rb+ efflux (k1 in gray, proportional to non-specific K+
conductance and k2, proportional to KATP specific K+ conductance), were calculated
from data shown in Figure 5.2. *p< 0.05 as compared to WT (unpaired Student’s t test).
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SUR2A-P429L, A475V or C1039Y channels, results in significantly higher basal
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rates compared to WT (Figure 5.2A and Figure 5.3A). P429L and A475V-based channels, but
not those composed of C1039Y, also showed significantly higher rate of efflux compared to WT
channels under MI conditions and in the presence of pinacidil (Figures 5.2B-C and 5.3B-C),
consistent with the gain of function(GOF) observed in the basal condition. Maximal efflux rates
(estimated using simultaneous exposure to MI and pinacidil) of P429L and A475V were
comparable to SUR2A-WT, implying similar channel densities at the cell surface (Figure 5.2D
and 5.3D). C1039Y showed significantly lower absolute fluxes in all stimulatory conditions
(Figures 5.2B-D and 5.3B-D), implying a lower channel density at the membrane (Figure 5.4).
The ratio of KATP-dependent (k2) rate constants in basal, MI and pinacidil to the maximal
KATP-dependent rate constant (k2 in MI+PIN) should reflect the relative activation of each
channel in these specific conditions. In the basal condition, the ratio was higher for all three
mutations, compared to WT, markedly so for C1039Y (Figure 5.4A). In pinacidil alone, while
only P429L and A475V reach significance, the ratio of active channels in all three mutations are
also increased (Figure 5.4C). Together, the results suggest that each mutant will result in higher
channel activity under any stimulatory conditions, particularly for C1039Y.
C1039Y (hC1043Y) overactivity results from decreased ATP-sensitivity via increased Po
86

Rb+ flux assays provide evidence for overactivity in CS mutants, but do not provide any

indication of underlying molecular mechanisms. We assessed the details of channel properties in
inside-out excised patch-clamp electrophysiology experiments. Intrinsic sensitivity to ATP
inhibition (in zero Mg2+), was similar for WT, P429L and A475V channels (Ki = 7-9 μM).
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Figure 5.4- Relative KATP conductance is markedly increased in basal and stimulated
conditions in intact cells expressing homomeric C1039Y KATP channels. The ratio of
the rate constants for KATP-dependent 86Rb+ efflux (k2) in basal and pinacidil- or MIstimulated conditions to the maximal activation (in MI+Pinacidil) is plotted for WT and
mutant channels. *p< 0.05 as compared to WT (unpaired Student’s t test).
64

However, KATP channels expressing C1039Y exhibited a significant right shift in ATP-sensitivity
(Ki = 21.3 µM)(Figure 5.5B). A diminished sensitivity to intracellular ATP may account, at
least in part, for the increased activity of C1039Y-based KATP channels in basal conditions in the
intact cell (Figures. 5.2A and 5.3A). Consistent with reduced channel density, the maximal
current in zero ATP was significantly lower in C1039Y channels than WT or the P429L and
A475V mutant channels (Figure 5.5C).
In PIP2 activation experiments, WT and C1039Y channels lost ATP sensitivity the more the
patch was exposed to PIP2. Simultaneously, the maximum currents for WT channels increased
while the maximum current in C1039Y channels activity remained the same (Figure 5.6). The
ratio of the maximum current in zero ATP over max current in PIP2 for WT patches (0.70 ± 0.11)
was significantly lower than that of C1039Y channel patches (1.26 ± 0.21), which implies
increased intrinsic activity from C1039Y channels.
Overactivity in P429L (hP432L) and A475V (hA478V) results from increased MgADP activation
We investigated the current response to intracellular MgADP in the presence of 0.1 mM ATP
(Figure 5.7A). MgADP-dependent activation was estimated as the ratio between the steady-state
activated current in MgADP+ATP and the maximal current in zero ATP, immediately after
excision (Figure 5.7B). In P429L, the relative current in MgADP was markedly higher than WT
for P429L and A475V channels. Using this analysis, the current was also statistically higher for
C1039Y channels. However, this analysis fails to account for the intrinsically lower sensitivity of
C1039Y channels to ATP inhibition. An alternative estimation for the stimulatory action of Mg-
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Figure 5.5- ATP-sensitivity is decreased in C1039Y channels. Representative excised patch
clamp recordings from COSm6 cells co-expressing Kir6.2 and WT or CS mutant SUR2 subunits
P429L, A475V or C1039Y (A). Membrane potential was held at -50mV, and negative currents
(plotted as upward deflections) were recorded continuously on-cell and in inside-out excised
patches exposed to KINT in the absence or in the presence of 0.01, 0.1 or 1 mM ATP; arrowheads
mark the point of excision. Dose-response data (mean ± SEM from 8-11 patches) was fit with
equation 3 to estimate the ATP concentration for half-maximal inhibition Ki: WT (9 µM), P429L
(9 µM), A475V (7 µM), and C1039Y (21 µM) (B). The maximum patch current determined
immediately following patch excision (mean ± SEM from 8-11 patches) (C).
66

Figure 5.6- C1039Y channels decreased ATP-sensitivity is due to increased Po
Representative KATP current traces following excision and in the presence of 1 mM ATP or 5
µg/µL-PIP2 as indicated(A). Relative Po determined as a ratio of the maximum steady-state
current in the patch upon excision, in the absence of nucleotides, over the maximum current
measured in PIP2. Individual patch data represented by symbols (n = 7-10); bars are the
means ± SEM respectively, where the relative Po for WT= 0.70 ± 0.11 and 1.26 ± 0.21 for
C1039Y (B).. *p< 0.05 as compared to WT (unpaired Student’s t test).
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Figure 5.7- P429L and A475V show enhanced MgADP activation Representative KATP current
traces following excision and in the presence of nucleotides as indicated (A). Relative MgADP
activation in individual patch data represented by symbols (n = 11-24); bars are the means ± SEM
respectively (B). *p< 0.05 as compared to WT (unpaired Student’s t test). Insert shows the mean
current measured in patches in the presence of 0.1 mM Mg-free ATP (from Figure 5.5B) subtracted
from the mean value of steady-state current measured in patches in the presence of MgADP (from
Figure 5.7A). Error bars represent the propagated error from both experiments half-time of activation
by MgADP (C).
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nucleotides is the ratio of current in MgADP+ATP to the current in Mg-free ATP alone (Figure
5.7B, inset). This analysis implies no difference in the MgADP activation of C1039Y and WT
channels. In addition, while the MgADP activation for P429L and A475V channels is more rapid
than WT, activation of C1039Y channel is even slower than WT (Figure 5.7C).
Gain of function is reduced in heteromeric mutant channels
All documented CS patients with mutations in ABCC9 are heterozygous. To mimic the predicted
heteromeric composition of channels in such patients we also expressed each mutation in a 1:1
ratio with SUR2A-WT plus Kir6.2-WT, and assessed channel activity by
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experiments (Figures 5.8 and 5.9). In all conditions P429L, A475V and C1039Y heteromeric
channels display no significant increases in the rates of 86Rb+ efflux, compared to WT channels
(Figures 5.8A and 5.9A). However, when normalized to the maximal efflux rates, channels with
heteromeric expression of C1039Y are still considerably more active than WT. Additionally, in
the heteromeric state, maximal C1039Y channel fluxes were markedly higher than in the
homomeric state (Figure 5.9D). Taken together, these results imply a partial rescue of the
surface expression of C1039Y subunits by WT subunits (Figure 5.7B-D and 5.8B-D).
Altered response to glibenclamide in C1039Y channels
Some NDM patients with GOF mutations in Kir6.2 or SUR1 have successfully switched from
insulin therapy to KATP channel inhibitors, such as glibenclamide (Zung et al., 2004). However, a
correlation between increased channel activity and the diminished effectiveness of such drugs
has been noted (Koster et al., 2005b). Therefore to test the effectiveness of glibenclamide on
overactive P429L, A475V or C1039Y channels, expressed both homomerically and
heteromerically, 86Rb+ efflux experiments were carried out in the presence of MI+ 10 µM
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Figure 5.8- Channel activity in cells expressing heteromeric P429L, A475V or C1039Ybased KATP channels. 86Rb+ efflux, as a function of time, was measured in GFP-transfected
control cells (dashed), and in cells transiently expressing reconstituted Kir6.2-based KATP
channels with WT or 1:1 mixtures of WT and P429L, A475V or C1039Y mutant SUR2
subunits, in basal conditions (A), in the presence of metabolic inhibitors (MI) oligomycin and
2-deoxy-d-glucose (B), or in the K+ channel opener pinacidil (C), or in the presence of both
MI and pinacidil (D). The data represent means + S.E.M. of 6-10 experiments. Flux data
were fit with equation 1 (GFP) to obtain the rate constant k1 or equation 2 to obtain the rate
constants for KATP-dependent efflux, k2 (Figure 5.9), where lines show mean fitted
relationships.
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Figure 5.9- KATP conductance normalized in the basal condition and in stimulated
conditions for heteromeric P429L, A475V or C1039Y-based KATP channels. The rate
constants for non-specific efflux (k1 represented by gray area) and KATP-dependent 86Rb+
efflux (k2), proportional to KATP specific K+ conductance, were estimated from data shown
in Figure 5.8. *p< 0.05 as compared to WT (unpaired Student’s t test).
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glibenclamide (Fig. 5.10). The time course of 86Rb+ effluxes shows an unusual behavior in that
although initial fluxes are markedly lower than in MI without glibenclamide, the inhibition is not
maintained through the time course of the assay. It is well understood that the inhibitory action
of glibenclamide is a complex function of the metabolic conditions, and decreases under
conditions of metabolic inhibition (Findlay, 1993; Koster et al., 1999). To account for this
behavior, the efflux data in glibenclamide were again fit by equation 2, where negative values for
k-2 result in the rate of efflux actually increasing with time for A475V and P429L channels. From
this analysis, the ratio of the k2 in MI+glibenclamide and k2 in MI alone approximates the
relative glibenclamide sensitivity (Figure 5.10C). While the sensitivity of A475V and P429L
channels was not different from WT, C1039Y channels are notably less sensitive. Qualitatively
similar results were obtained with channels expressed in heteromeric mixture with WT subunits
(Figures 5.9B,D). As discussed below, this is consistent with similar findings for SUR1
mutations that results in increased activity of the resultant KATP channels.
5.3 Discussion
Distinct mechanisms of KATP GOF in Cantu Syndrome ABCC9 mutations
Cantu Syndrome (CS) is a rare disease characterized by complex vascular and skeletal
anomalies, the underlying cellular and molecular mechanisms of which we are only now
beginning to understand (Nichols et al., 2013). The majority of genotyped CS patients are
heterozygous for mutations in the genes encoding ABCC9 (SUR2) (Harakalova et al., 2012; van
Bon et al., 2012) in most cases, and KCNJ8 (Kir6.1) (Brownstein et al., 2013; Cooper et al.,
2014) in others. A select few of these mutations, to date, have been shown to form overactive
KATP channels (Cooper et al., 2014; Harakalova et al., 2012), but most remain unexplored. Here,
we characterized three CS-associated ABCC9 mutations, namely P429L (hP432L), A475V
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Figure 5.10- Decreased sensitivity to glibenclamide inhibition in C1039Y channels. 86Rb+ efflux, as a
function of time, was measured in GFP-transfected control cells, and in cells transiently expressing KATP
channels composed of Kir6.2 plus WT or mutant SUR2 subunits (A), as well as in cells expressing 1:1
mixture of WT and mutant SUR2 subunits (B). Experiments were performed in MI+ glibenclamide. The
data represent the means + S.E.M. of 3-6 experiments. Data were fit with equation 2 to obtain rate constants
for KATP-dependent efflux (k2). k2.in glibenclamide + MI was divided by k2 in MI for each condition(C,D).
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(hA478V) and C1039Y (hC1043Y), that localize to distinct regions of the SUR2 protein
(Figure 5.1). Each mutation leads to KATP channel gain of function (GOF) (Figures 5.2-5.7),
consistent with previous findings on isolated CS-associated ABCC9 mutations (Harakalova et al.,
2012).
In the only previous assessment of CS-associated ABCC9 mutations, Harakalova et al.
measured channel sensitivity to ATP in the presence of Mg2+. Mg-nucleotides have complex
activatory/inhibitory effects on KATP channels: MgATP can both inhibit the Kir6.X subunit and
be hydrolyzed to activatory MgADP at the SUR subunits (Nichols, 2006). Therefore, such an
analysis cannot separate mutant effects on ATP inhibition from those on Mg-nucleotide
activation. By separately assessing channel activity in response to Mg-free ATP and to MgADP
we show that CS-associated ABCC9 mutations lead to increased channel activity via different
mechanisms, as has also been observed with NDM-associated ABCC8 mutations (de Wet et al.,
2008; de Wet et al., 2007; Masia et al., 2007; Zhou et al., 2010). Specifically, we demonstrate
two mechanisms of increased channel activity, where P429L and A475V channels results from
increased MgADP activation and C1039Y channels results predominantly from decreased ATP
sensitivity.
KATP mutations in SUR1 have been shown to decrease ATP-sensitivity (Takagi et al.,
2013; Tarasov et al., 2008). There are at least two mechanisms to decrease ATP sensitivity in
KATP channels including decreased ATP binding or increased open probability (Po) (Denton and
Jacobson, 2012). Considering the SUR2-C1039Y mutation is not likely to disrupt binding of
ATP to the Kir6.X subunit we tested for changes in channel Po. The simple gating model,
Ci↔C↔O, Ci represents closed channels inhibited by ATP, C represents intrinsic closing and O
represents open channels. PIP2 activates KATP currents by increasing the intrinsic Po, or in
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reference to a simple gating model, PIP2 forces channels to stay in the open state, preventing
transition from C to Ci by ATP binding (Shyng and Nichols, 1998). Therefore, the ability of PIP2
to decrease ATP sensitivity, but not increase the maximum currents from C1039Y channels
imply the Po of these channels is near 1 (relative Po = 1.26 ± 0.21) which is significantly higher
than the Po for WT channels (relative Po = 0.70 ± 0.11) (Figure 5.6), and thus ultimately results
in decreased ATP sensitivity (Figure 5.5).
In addition to increasing channel activity, homomeric expression of C1039Y appears to
decrease expression of channels in the membrane. A similar dual effect of GOF mutations in
both Kir6.2 (Lin et al., 2013) and SUR1 (Zhou et al., 2010) has previously been shown. In these
previous examples, decreased surface expression was demonstrated by western blot analysis.
Significant rescue of channel activity in heteromeric C1039Y/WT channels is consistent with the
patterns from such mutations (Figures 5.8 and 5.9), suggesting that in addition to reducing
ATP-sensitivity of expressed channels, C1039Y also decreases KATP surface expression.
Implications for tissue pathology in in Cantu Syndrome
Kir6.1 GOF mutations have also been found in two Cantu Syndrome patients (Brownstein et al.,
2013; Cooper et al., 2014), confirming Kir6.1/SUR2 as the key subunit combination generating
the overactive channels. Given the experimental difficulty of recording Kir6.1/SUR2 currents
(Cooper et al., 2014), we used Kir6.2+SUR2A channels in the present study. ABCC9 encodes
two splice variants: SUR2A and SUR2B, which vary only in the last 40 amino acids. All CSassociated SUR2 mutations identified to date are located within the core of the SUR2 protein,
such that these mutations will be present in both SUR2A and SUR2B. SUR2A is predominant in
skeletal muscle and heart, while SUR2B is expressed in the vasculature. Kir6.1/SUR2B may be
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the more dramatically affected combination, since vascular phenotypes seem to predominate in
CS patients (Nichols et al., 2013). Conversely, neither skeletal muscle weakness nor shortening
of the QT interval on the ECG have been noted, as might be expected if Kir6.2/SUR2A were
markedly activated.
The severity of disease varies between Cantu Syndrome patients such that not all reported
features are exhibited by all patients. Direct comparison of the phenotypes of patients carrying
the A475V and C1039Y equivalent mutations (Harakalova et al., 2012) revealed hypertrichosis,
macrosomia, macrocephaly, coarse features, cardiac anomalies, and umbilical hernia to be
common

to

both.

However,

pulmonary

hypertension,

cardiomegaly,

osteopenia,

hyperextensibility and lymphedema were only reported for the A475V equivalent patient. The
reduced sensitivity to ATP inhibition, due to the C1039Y mutation, results in greater relative
basal channel activity than the enhanced Mg-nucleotide activation, due to A475V. However, a
less severe disease phenotype for C1039Y suggests that reduced expression of this mutation may
also be a consequence in vivo, as has also been reported for SUR1 NDM mutations (Zhou et al.,
2010).
Implications for therapeutic intervention in Cantu Syndrome
Finally, sulfonylureas, which inhibit KATP channels via interaction with the SUR subunits, are
effective treatments for NDM patients with ABCC8-activating mutations (Babenko et al., 2006),
and are promising potential therapies for Cantu Syndrome (Nichols, 2013 #7510). However,
GOF mutations in Kir6.2 (Koster et al., 2005a) and SUR1 (Takagi et al., 2013) frequently also
decrease sensitivity to sulfonylureas, which may result in a lack of sulfonylurea therapeutic
efficacy in patients with these mutations. Assessment of
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demonstrates that WT, P429L and A475V channels show complex time dependence of efflux
(Figure 5.10). Each required a very negative k-2 rate constant, which is indicative of channel
activation versus inactivation. We interpret this activation to be reflective of a loss of
glibenclamide inhibition over time. Divergent from the others, the k-2 for C1039Y has a very
small positive value, which is consistent with some channel inactivation. Similarly, k2 values in
MI+glibenclamide WT, P429L and A475V channel activity drops to less than 10% in MI alone
while C1039Y activity drops to ~50%. Taken together this would indicate that the C1039Y
channel is glibenclamide insensitive. However, in general, SUR2 sensitivity to sulfonylureas is
much lower than SUR1-sensitivity (Dorschner et al., 1999). Therefore, given the further
reduction in drug sensitivity of GOF mutants, the introduction of sulfonylureas to treat CS
patients is likely to require high doses, which would result in undesired inhibition of SUR1based KATP channels. SUR1 inhibition can lead to hypoglycemic effects, which will need to be
carefully considered. Such concerns may ultimately make necessary the development of Kir6.1
or SUR2 specific inhibitors to provide a safer and more effective treatment options for CS
patients.
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CHAPTER j: DISCUSSION
GOF in KATP channel underlies CS
In 2012, genetic analysis of 2 cohorts of CS patients demonstrated that the majority have
mutations in ABBC9, which encodes the SUR2 protein (Harakalova et al., 2012; van Bon et al.,
2012). Initial studies of a few CS-SUR2 mutations expressed with Kir6.2 demonstrated increased
KATP channel activity (Harakalova et al., 2012). My analysis of new, previously uncharacterized
CS-associated SUR2 mutations confirms this effect. In 2013, two additional CS patients were
reported (Brownstein et al., 2013; Cooper et al., 2014) who presented with the hallmark features
of CS, but were negative for a SUR2 mutation. Instead, both carry a mutation in KCNJ8 (Kir6.1V65M and C176S). I also demonstrate that each of these CS-Kir6.1 mutations (V64M and
C176S) also increase KATP channel activity. Therefore, having demonstrated that both SUR2 and
Kir6.1 CS-mutations increase KATP channel activity, I conclude that gain of function (GOF) in
KATP channel activity underlies CS. The previous data showing that multiple SUR2 mutations
result in a GOF in channel activity was strong evidence to support increased KATP channel
activity underlying CS. However, the demonstration that CS- associated mutations in Kir6.1 also
increase KATP channel activity was crucial in confirming this, as there are reports of SUR2
involvement in KATP channel independent activity (Aggarwal et al., 2010; Stoller et al., 2010).
Molecular basis of KATP channel gain of function
Gain of Function (GOF) in channel activity can arise from increases in channel activity and/or
from increased channel expression. The majority of Neonatal Diabetes Mellitus (NDM) patients
carry mutations in Kir6.2 or SUR1 that increase KATP channel activity (Babenko et al., 2006;
Gloyn et al., 2004). Several mechanisms by which NDM mutations enhance KATP channel
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activity have been described (Denton and Jacobson, 2012). For example, Kir6.2 NDM mutations
have been shown to enhance channel open probability (Po) (Mannikko et al., 2009) or to decrease
ATP binding (Proks et al., 2004). SUR1 NDM mutations have been shown to enhance KATP
channel activity by enhancing ATPase activity (de Wet et al., 2008), by allosteric changes that
indirectly decrease ATP sensitivity (Babenko et al., 2006), or by increased MgADP activation
(Masia et al., 2007). However, no molecular details of CS-causing Kir6.1 or SUR2 mutation
mechanisms have previously been described.
In this project, I have sought to address this question. To do this, I examined nucleotide
sensitivity for SUR2 mutations in inside out patch clamp experiments. For Kir6.1 mutations,
nucleotide sensitivity was also assessed and, by estimating PIP2 activation, I also determined
relative Po. CS-associated Kir6.1 and SUR2 GOF mutations result from several distinct
mechanisms. I have, for example, demonstrated that SUR2 mutations can disrupt response to
ATP or MgADP. The SUR2-C1039Y mutation results in GOF, by indirectly decreasing
sensitivity to ATP inhibition without affecting MgADP activation. Conversely, both SUR-P429L
and A475V increase channel activity by enhancing MgADP activation. A third mechanism, in
both Kir6.1 mutations (Kir6.1-V65M and C176S), enhances Po, thereby indirectly decreasing
channel sensitivity to ATP inhibition. Additionally, because one of the SUR2 mutations
(C1039Y) unexpectedly demonstrates decreased trafficking, surface expression may also
confound disease presentation.
Kir6.1/SUR2 expression and CS symptoms
At the tissue level, the effects of NDM and CS mutations depend on the tissues where the
channels are expressed, and on how sensitive each tissue is to KATP channel activity. Kir6.1 is
expressed ubiquitously and has been confirmed in the vasculature (Inagaki et al., 1995c). SUR2
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can be alternatively spliced into two major isoforms: SUR2A and SUR2B (Isomoto et al., 1996).
The splice variant SUR2A is expressed in the heart and skeletal muscle (Chutkow et al., 1996).
In parallel to Kir6.1, the splice variant SUR2B is also expressed ubiquitously and confirmed in
the vasculature (Chutkow et al., 1996; Inagaki et al., 1995c).Conversely, Kir6.2 and SUR1 are
expressed primarily in pancreatic beta cells, brain, heart and skeletal muscle (Inagaki et al.,
1995a).
There have been several reports of tissues expressing both Kir6.1 and Kir6.2 (Insuk et al.,
2003; Teramoto et al., 2009). However, to date, there appears to be no overlap in symptoms of
CS and NDM patients experience. CS patients generally present with cardiomegaly,
hypertrichosis, macrocephaly, osteochrondyslpasia, and macrosomia (Grange 2006, van Bon
2012, and Harakalova 2012). Conversely, NDM patients experience hyperglycemia and
hypoinsulinemia along with neurological complications in the most severe cases. This lack of
overlap in symptoms implies that where expression of pore-forming subunits overlaps, the
predominance of non-mutated pore-forming subunits might be protective.
Potential for CS genotype/phenotype correlation
NDM presents with varying severity, from Transient NDM (TNDM), to Permanent NDM
(PNDM), to developmental delay, epilepsy and neonatal diabetes (DEND) (Naylor et al., 2011).
The severity of the disease correlates with the molecular severity of the Kir6.2 or SUR2
mutations (Flanagan et al., 2009; Hattersley and Ashcroft, 2005). TNDM patients have
hyperglycemia and hypoinsulinemia that is present at birth, but is not permanent. The Kir6.2 or
SUR1 mutations associated with this form of NDM have weak shifts in ATP sensitivity or
enhancement of MgADP activation (Gloyn et al., 2005; Proks et al., 2004). PNDM patients have
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hyperglycemia and hypoinsulinemia that also appears within the first 6 months of life, but
persists throughout life. Compared to TNDM mutations, the Kir6.2 and SUR1 mutations in this
form of NDM typically have larger shifts in ATP sensitivity or enhancement of MgADP
activation (Gloyn et al., 2004; Proks et al., 2004). Along with the diabetes, DEND patients can
have developmental delay and epilepsy. Intermediate DEND (iDEND) is a form of DEND with
milder developmental delay and no epilepsy. Kir6.2 and SUR1 mutations causing isDEND and
DEND have the most severe shifts in ATP sensitivity or enhancement of MgADP activation
compared with all other forms of this disease (Proks et al., 2004; Proks et al., 2006; Proks et al.,
2005). Is there a range of symptoms in CS? CS patients generally present with cardiomegaly,
hypertrichosis, macrocephaly, osteochrondyslpasia, and macrosomia (Grange 2006, van Bon
2012, and Harakalova 2012).There are also symptoms that are only found in small subsets of
patients, including patent ductus arteriosus (PDA), pericardial effusions, and valvular
abnormalities. This raises the question: do CS mutations correlate with symptomatic
presentation?
In considering this question with just the patients with Kir6.1 or SUR2 mutations which I
have functionally described (Table 6.1), the major common symptoms were present in all. The
mutations carried by patients who have all the major symptoms with the addition of at least one
of the rare symptoms included: Kir6.1-V65M, C176S or SUR2-A475V.Based on
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experiments (Figures 3.1A and 3.2A, Figure 4.1, and Figures 5.2A and 5.3A) these mutations
result in the largest fluxes in the basal and pinacidil stimulated conditions. Of the other SUR2
mutations considered, A475V has one of the largest increases in relative 86Rb+ efflux under basal
conditions. Both the CS-Kir6.1 patients carrying the Kir6.1-V65M and Kir6.1-C176S mutations
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Table 6.1- Cantu Syndrome Mutations and Clinical Symptoms.

Gender
Inherited (Y/N)
Alive (Y/N)
Coarse face
congential
hypertichosis
Macrosomia
at birth
Macrocephaly
developmental
delay
cardiomegaly
structural
cardiac
anaomalies
pulmonary
hypertension
pericardial
effusion
hypertrophic
and/or dilated
cardiomyopathy
lymphedema
PDA

Kir6.1V65M
M
N
Y
+

Kir6.1C176S
M
N
Y
+

SUR2P429L
F
N
Y
+

SUR2A75V
F
Y
Y
+

SUR2A75V
M
unk
Y
+

SUR2C1039Y
F
N
Y
+

+

+

+

+

+

+

+
unk

+
+

+
unk

+
+

+
+

+
+

mild

+

-

+

-

-

+

+

+

-

+

-

+

+

-

+

+

+

+

-

-

+

-

-

-

-

-

-

-

unk

+
-

+

+
-

-

unk
+

-

unk

+

-

unk

unk

unk

The + symbols indicates clinical symptoms present in patients, - symbol indicates clinical
symptoms that are absent in the patients. The unk designation indicates symptoms not test and/or
reported in the patients. Common CS symptoms are indicated in black and symptoms present only
in small subsets of CS patients are indicated in red.
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have similar symptoms and the mutant channels displayed comparable rates of
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the basal condition (Figures 4.1 and 4.2). Taken together, potential genotype/phenotype
correlations exist, but additional studies in a larger set of CS Kir6.1 and SUR2 mutations will
need to be done to accompany the clinical findings reported.
Potential for treating CS
There is currently no specific treatment for CS. Sulfonylureas bind directly to the SUR subunits
of KATP channel to inhibit KATP channel activity (Ashfield et al., 1999).With the understanding
that the molecular basis of CS is GOF in KATP channel activity, use of a sulfonylurea drugs, such
as glyburide, a KATP channel-specific inhibitor that is currently used to treat diabetes (Feldman,
1985), may be a treatment option. However, a potential detrimental side effect to using
glyburide, or other sulfonylurea drugs, as a CS treatment option, is that KATP channels containing
SUR1 are typically ~100fold more sensitive to these drugs than KATP channels containing SUR2
(Gribble et al., 1998). Even SUR2 mutations with reduced sulfonylurea sensitivity may be
capable of being inhibited partially by these drugs, but perhaps require higher doses. However, in
addition to the efficacy of these drugs to inhibit SUR2 based channels, they will also bind and
inhibit SUR1-based channels from increasing insulin secretion, which can result in
hypoglycemia. Thus, along with the potential benefits of administering sulfonylureas to CS
patients, there would also be a risk of patients becoming hypoglycemic which, if left unmanaged,
can be lethal.
An alternate option to sulfonylureas would be inhibitors that target KATP channels
composed of Kir6.1+SUR2A specifically. Currently, there is a reportedly Kir6.1-specific
inhibitor, U-37883 or PNU-37883A. Electrophysiology experiments, in a heterologous
expression system, demonstrate that PNU-37883A preferentially inhibits ~80% of Kir6.1 based
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channels at 100µM, but also partially inhibits ~15% of Kir6.2-based channels (Surah-Narwal et
al., 1999). While this Kir6.1 selective inhibitor is not be perfect, it may be a good starting point
for the development of a specific CS treatment.
Is there a Kir6.1/SUR2 loss of function (LOF) disease?
Kir6.2 and SUR1 mutations which result in a loss of function (LOF) in KATP channel activity
underlie Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) also known as congenital
hyperinsulinemia (Darendeliler et al., 2002). PHHI is characterized by increased plasma levels of
insulin in hypoglycemic conditions along with decreased levels of ketone bodies and free fatty
acids (Aguilar-Bryan and Bryan, 1999), i.e., the opposite of NDM. CS has now been identified
as the result of Kir6.1/SUR2 GOF, but there is currently no known LOF disease caused by
Kir6.1/SUR2 mutations. Sudden Infant Death Syndrome (SIDS), is characterized by the sudden
and usually unexplained death of an infant (Dawes, 1968). Two Kir6.1 mutations (in-frame
deletion E332del and a missense mutation V346I) identified in babies with SIDS results in LOF
in KATP channel activity, when expressed with SUR2 (Tester et al., 2011). Though there are no
reported SIDS patients to date with SUR2 mutations, multiple SIDS babies with a Kir6.1-LOF
mutation make SIDS a strong candidate Kir6.1/SUR2 LOF disease.
The tissues impacted by GOF in Kir6.1 and SUR2 most commonly include the heart, hair,
vasculature and bone (Nichols et al., 2013). So what would be the result of LOF in those same
tissues? Most CS patients have enlarged hearts (Grange et al., 2014) and, thus, in a disease linked
with a LOF of KATP channel activity, a small heart might be anticipated. The opposite of the
failure of the ductus arteriosus to close, which is seen in CS, would be premature closure. When
considering the hair of LOF patients, the converse of excessive hair growth, i.e., reduced or no
hair would be potential symptoms. In the vasculature, CS patients have low blood pressure, and
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the opposite of that, which may be present in LOF patients, would be hypertension. Finally, KATP
channels have been reported in mesenchymal cells, which differentiate along an osteogenic
lineage to form bone. Considering these various symptoms in different target tissues, CS may
therefore, provide insights into Kir6.1/SUR2 LOF disease(s)
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